Antibody glycoengineering for drug delivery applications by Sehgal, Drishti
 
ANTIBODY GLYCOENGINEERING 






A Thesis  
  
SUBMITTED TO THE FACULTY OF  









IN PARTIAL FULFILLMENT OF THE REQUIREMENTS  
FOR THE DEGREE OF  












December 2019  
  ii 
  © Drishti Navin Sehgal 2020 
  
  
    
  
  iii 
Acknowledgements  
The past five years were a tremendous learning experience. Several people have 
contributed selflessly to my growth, and I take this opportunity to thank them.  
I cannot thank my adviser, Dr. Jayanth Panyam, enough for his guidance and support 
during my graduate studies. His enthusiasm towards science was a constant source of 
inspiration for me. I have yet to meet as patient and understanding person as him.  
My parents and sister Isha for their constant love and support. It is my parents who 
deserve the credit for my academic endeavors. This would have been a much harder 
journey without their daily words of encouragement.  Thank you Piyush, for always 
believing in me and adding flavor to my boring life. I would have been much crankier and 
grouchier person by now, if I had not met you.  
I am also extremely thankful to the Department of Pharmaceutics. Specifically, Katie 
James and Amanda Hokanson, for being my magical genies and making my life a lot easier. 
Dr. William Elmquist, Dr. Tim Wiedmann and Dr. Ben Hackel for being in my thesis 
committee and their valuable time. I would also like to thank Dr Swayam Prabha for always 
guiding me through all my challenges.  
I would like to thank past and present lab members. Specifically, Ameya, Stephan, 
Hynjoon and Tanmoy for teaching me everything patiently. Buddhadev, for always being 
helpful and guiding me in right direction. Manan, thank you for your contribution in 
completing my thesis projects.  
I have had the opportunity to work with several of Dr. Panyam’s collaborators. This 
has enriched my PhD experience. I would particularly thank Dr Thomas Griffith for 
greeting me with warm welcome and allowing me to use his recourses. I would also like 
  iv 
to thank Tammy for helping me with all my experiments in Griffith Lab. I also appreciate 
the technical assistance offered by Brenda Koniar, Jane Diamond, Jim Fisher, Guillermo 
Marques and the flow cytometry core.  
Finally, I would like to thank my friends and family for always showering me with 
their love and support. You all always reminded me to have fun outside lab.  
  





This thesis is dedicated to my parents for their unconditional love and support. 
  
  vi 
Abstract  
Monoclonal antibodies (mAbs) are frontline drugs for the treatment of many diseases 
including cancer 1 and rheumatoid arthritis 2. In addition to their natural role as neutralizers 
of pathogens and toxins as well as in the recruitment of immune elements (complement, 
improving phagocytosis, antibody dependent cytotoxicity), they can be used as carriers for 
tumor-targeted delivery of therapeutic and diagnostic agents 3. However, conjugation of 
drug or drug-encapsulated nanoparticles to antibodies can often result in reduced affinity 
of the antibody towards the target antigen.  
The overall objective of this thesis is to advance a new antibody glycoengineering 
technology that will allow for facile synthesis of antibody-based drug delivery systems. Most 
therapeutic mAbs are of the IgG class, which contains a glycosylation site in the Fc region 
at position 297 4. In chapter 2, we investigated a glycoengineering strategy that enables the 
introduction of artificial azide groups at this glycosylation site without affecting their 
antigen affinity. This is based on the observation that glycosyltransferases present in 
mammalian cells can incorporate non-natural sugars (e.g., azido mannose) at glycosylation 
sites on an IgG molecule during the post translational modification. The azide groups in 
these artificial sugars are then available to react with alkynes through copper-catalyzed 
‘click’ chemistry or with strained alkynes such as dibenzyl cyclooctyne (DBCO) allowing 
for biorthogonal, copper-free ‘click’ chemistry. Because the sugars are added reproducibly 
and at a site that does not affect antigen binding, the glycoengineering technology would 
overcome problems associated with traditional conjugation strategies. Using this approach, 
azide groups were introduced in anti-CD133 and anti-perlecan (AM6) antibodies. Further, 
  vii 
the azide groups were available to react with various DBCO conjugates including 
fluorophores, drug molecules and nanoparticles. Importantly, the addition of artificial 
sugar and subsequent azide-alkyne reaction did not affect the affinity of the antibody for 
the target antigen.  
Antibody–drug conjugates (ADCs) have emerged as the next generation anticancer 
therapeutic agents. In chapter 3, glycoengineered AM6 antibody was used to generate an 
ADC with monomethyl auristatin E (MMAE) as the cytotoxic drug. The glycoengineering 
approach resulted in an ADC with a DAR of 2-3 drug molecules per antibody. The AM6-
MMAE conjugate demonstrated enhanced cell kill in vitro and significantly improved 
anticancer efficacy in vivo compared to free MMAE.   
Similarly, in chapter 4, glycoengineered AM6 antibody was used to generate 
antibody conjugated polymeric nanoparticles loaded with paclitaxel. These perlecan-
targeted nanoparticles showed enhanced antitumor efficacy in vitro and in vivo in TNBC 
tumor models. Similarly, antibody conjugated nanoparticles showed enhanced antitumor 
efficacy in vitro and complete tumor growth inhibition in vivo in a non-muscle invasive 
bladder cancer model. We expect that this glycoengineering strategy will prove to be a 
unique platform technology that will have a significant impact on antibody-based 
therapeutics.     
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Chapter 1: Introduction   
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1.1. Introduction to Monoclonal Antibodies  
  
The hypothesis that the immune system recognizes cancer cells as foreign has 
gained much traction in the past two decades 5. In fact, a large fraction of the newer 
class of anti-cancer therapeutics are largely focused on modulating the immune system 
to improve recognition of cancer cells 6. Following suit, antibodies have become a 
major focus for the development of new cancer therapeutics 7.   
Over the past three decades, there has been a consistent increase in the number 
of monoclonal antibody products that have been approved 8. Their stability, minimal 
toxicity (relative to cytotoxic drugs) and pharmacokinetic properties are some of the 
desirable attributes for pharmaceutical development 1. The key properties of antibodies 
that enable their widespread application as immuno-therapeutics include their 
specificity and high affinity for the target antigen 1,9. In addition, their clinical success 
is a definite motivation for further investment, considering that of the 41 novel drugs 
that have been approved by the USFDA, 16 are some form of an antibody (as of 




1.2. Development of Monoclonal Antibodies  
  
The innate arm of the immune system is effective in defending the body against 
pathogens that are ‘typical’ in nature or those that have classical molecular patterns.  
However, in order to fight a wide range of insults, the immune system also consists of 
an adaptive arm. B cells, a part of the adaptive immune system, recognize antigens 
through  
                                                                                                                                               3  
the B cell receptor 10,11. Upon Helper T cell mediated stimulation, B cells secrete 
antibodies that are able to specifically bind to these foreign antigens. Circulating 
antibodies, also  
termed as immunoglobulins (IgGs) 11,12, are then able to eliminate antigens by two 
potential mechanisms: one involves directly binding to and neutralizing the antigen, 
and the other is to recruit innate immune components (complement proteins, NK cells, 
macrophages, and dendritic cells) that are able to eliminate the antigen from the system 
10–12.Thus, the idea behind the development of exogenous monoclonal antibodies is to 
enable the human body to recognize pathogens or tumor antigens that it may have 
missed.  
B cells can develop antibodies to virtually any type of antigen, including 
pathogens as well as small molecules 13. They secrete antibodies that bind to a vast 
variety of antigens. On average, a human has the ability to produce greater than 108 - 
1010 different types of specific antibodies due to specialized processes of the immune 
system 14. The hybridoma technology, developed by Kohler and Milstein, was an 
attempt to utilize these ‘specialized processes’ for the development of clinical 
therapeutics 15. It involved immunizing animals (often mice or rabbits) repeatedly with 
an antigen of interest causing B cells to secrete antibodies specific to that antigen. 
Along with several following downstream processes, this technology provided 
researchers with the much-needed capability to artificially develop antibodies against 
specifically selected antigens. In addition, it also provided a means to produce large 
quantities of antibodies in vitro 16,17. Kohler and Milstein were awarded the 1994 Nobel 
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Prize in Medicine/Physiology for their work in the development of hybridoma 
technology 18.However, due to their non-human origin, hybridoma antibodies have 
had limited clinical success19. Mouse antibodies suffer from significant 
immunogenicity and are unable to interact with other immune components when 
administered in humans20. These issues were addressed by the development of 
chimeric and humanized antibodies from hybridoma clones, that replaced portions of 
the mouse antibody sequence with human antibody sequences 21,22. This led to the 
development of several tumor-targeted antibodies that have been clinically successful. 
The first chimeric monoclonal antibody approved for cancer treatment was Rituximab 
(Rituxanâ) 23, an anti- human CD20 binding antibody with mouse and human 
sequences combined13.  
Twenty four years after Kohler and Milstein received the Nobel prize for 
hybridoma work, Sir Gregory Winter and George Smith were awarded the Nobel Prize 
for phage display 24. The technology has allowed scientists to develop fully-human 
antibodies against virtually any antigen of interest, in vitro. This method uses large, 
diverse libraries of bacteriophage (bacterial viruses) displaying antibody fragments on 
their surface for in vitro high-throughput screening of antibody fragments against the 
desired peptide/antigen. Sequential enrichment of antibody fragments that display 
specificity for the given target eventually leads to a manageable number of candidates 
that can be reformatted into fully human IgGs using modern molecular biology 
techniques. Adalimumab (Humiraâ) 25, the first approved monoclonal antibody 
developed using phage display, is used for the treatment of various auto-immune 
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disorders 26. It was approved in the US in 2002 and has since topped the list of highest 
selling drugs in the US 27.  Phage display was a significant advancement over the 
hybridoma technology, that despite its success, suffered from several limitations such 
as being labor and time intensive. In addition to being an immensely useful tool in the 
development of antibodies, phage display can also be utilized for the discovery of 
novel targets 28. Analogous to the use of tumor gene expression profiles to evaluate 
the presence of mutations or anomalous overexpression, phage display can be used to 
identify new targets in their native, physiological format.   
  
1.3. Antibody Structure and Classification  
  
Antibodies can be classified into five different sub-classes based upon their 
structure. These include IgA, IgD, IgM, IgG and IgE 9. Each sub-class has its own 
unique but complementary immune functions. The most abundant type of antibody in 
blood is IgG. It comprises 10-20% of the total plasma protein component and about 
80-90% of the total plasma antibody component 9,29. IgG is also the most extensively 
studied class of antibodies, representing more than 70% of all antibody based 
therapeutics 30. From here on, any reference to antibodies (unless otherwise specified) 
will be made with respect to IgG antibodies. Each IgG molecule is a Y-shaped 
molecule (~150 kDa) consisting of four polypeptide chains, two identical heavy chains 
(~50 kDa each) and two identical light chains (~25 kDa each) 9. Two disulfide bonds 
link the two heavy chains together and one disulfide bond, each, links the two heavy 
chain-light chain pairs together (Figure 1.1) 11. In humans, there are five types of heavy 
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chains (α, µ, γ, ε and δ) that determine the antibody classification of IgA, IgM, IgG, 
IgE and IgD, respectively. There are also two types of light chains classified as κ and 
λ 9.  
  
 
Figure 1.1: Structure of an IgG antibody. Image modified from Janeway’s  
Immunobiology 
Each light chain can be further sub-divided into the constant (C) domain and the 
variable (V) domain i.e., CL and VL, respectively. The heavy chain can be sub-divided 
into three constant domains and one variable domain i.e. CH1, CH2, CH3 and VH, as well 
as an additional hinge region between CH1 and CH2 (Figure 1.1). Antibodies of classes 
other than IgG also have the same basic framework of heavy and light chains; 
however, variability in the heavy chain allows for different effector functions for 
different sub- classes.  
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Regions of an antibody can be grouped together structurally or functionally. 
Structurally, VL and VH are grouped together to form the variable region that is 
responsible for the expansive diversity observed in antigen binding 11. More 
specifically, within each variable domain (VH and VL) are found three hypervariable 
regions or complementarity determining regions (CDRs) that allow for the highly 
diverse antigen binding 31. Thus, each antibody can have six unique CDRs. 
Polypeptide chains outside the CDRs but within the variable domains are termed as 
‘framework’. On the other hand, the CL and CH regions are grouped together to form 
the constant region that varies only subtly, allowing for different effector functions.  
Functionally, VL, CL and VH, CH1 together form the ‘fragment antigen binding’ 
(Fab) 11. The presence of two Fab arms makes antibodies bivalent in nature i.e., they 
simultaneously bind to two antigen molecules, thus increasing the total strength of 
interaction through avidity 9. On the other end, CH2 x2 and CH3 x2 together form the  
‘fragment crystalline’ (Fc) portion of the antibody or the ‘stem’ of the antibody 11.  
 
Thus, an antibody can be thought to have two primary functions; the first, to bind 
to a unique target antigen, and the second, to bind to different components of the 
immune system. As the name suggests, the Fab arm of an antibody binds to the target 
antigen, whereas the Fc region binds to different immune components and determines 
its effector function. The Fc region is also a critical determinant of antibody 
pharmacokinetics, a property that is significantly different from that of traditional 
small molecule compounds. It is important to note here that, even though the Fab 
domains make antibodies unique and desirable for pharmaceutical development, the 
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Fc domains are critical to antibody function and influence the outcome of therapeutic 
antibodies.  
Therapeutic mAbs and derivatives have an asparagine (Asn)-X-Ser/Thr (where 
X is any amino acid except a Pro) consensus sequence for N-glycosylation at the 
position Asn297 in the heavy chain of the CH2 constant domain 32. Some therapeutic 
mAbs also bear additional glycosylation in the Fab domain such as at Asn88 of the 
VH region in the case of cetuximab7. In addition, some of the Fc-fusion partner 
molecules such as etanercept and B cell-activating factor receptor 3 (BR3)–Fc also 
possess O-linked glycans 33,34. Alteration of glycan compositions and structures can 
cause conformational changes of the Fc domain, which could change binding affinity 
to Fc receptors, resulting in changes to immune effector functions 35,36. Fc effector 
functions include complement-dependent cytotoxicity (CDC), antibody-dependent 
cell-mediated cytotoxicity (ADCC), and antibody-dependent cell-mediated 
phagocytosis (ADCP) 35. All three effector functions are triggered by the formation of 
immune complexes, which then recruit complement proteins and/or effector cells 32.  
1.4 IgG N-glycan structure and biosynthesis  
 
Unlike other serum proteins, the N-linked glycans of human IgGs are typically 
biantennary complex structures (Figure 1.2). A conserved core structure is composed 
of two N- acetylglucosamine (GlcNAc), three mannose, and two GlcNAc residues that 
are b-1,2 linked to a-6 mannose and a-3 mannose, forming two antennae. Additional 
monosaccharides extended from the core may be present. Depending on the host 
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glycosylation machinery, additional fucose (Fuc), galactose (Gal), bisecting GlcNAc, 
and sialic acid including N-acetylneuraminic acid (NANA) or N-glycolylneuraminic 
acid (NGNA) residues, may be added to the core. Glycans present considerable 
heterogeneity with more than several hundred possible glycoforms because of the 
random pairing of heavy-chain glycans with different structures 7,37. The a-1,6 arm of 
the biantennary glycan extends along the hydrophobic face of the CH2 amino acid 
backbone where the polar nature of the carbohydrate protects the underlying 
hydrophobic polypeptide. The a-1,3 arm of the glycan extends toward the interstitial 
space formed by the CH2–CH3 dimer. The glycans on opposite Asn297 residues of 
each heavy chain interact and maintain the conformation of the Fc domain. As such, 
changes in Fc glycosylation can alter the Fc conformation and subsequent binding to 
Fc receptors 38.  
Antibody N-linked glycan biosynthesis follows the same process as for other 
glycoproteins 39–41. A preassembled Glc3Man9GlcNAc2 oligosaccharide is 
transferred to Asn297 of the IgG heavy chain by an oligosaccharyl transferase complex 
in the endoplasmic reticulum, followed by glycosidase-mediated sequential removal 
of three Glc residues and a mannose residue to form Man8GlcNAc2. After transition 
to the cis-Golgi apparatus, three additional mannoses are trimmed by mannosidase to 
form a Man5GlcNAc2 oligosaccharide. Once in the medial golgi, the N-
acetylglucosaminyltransferase–I (GnT- I) enzyme mediates the transfer of GlcNAc 
from UDPGlcNAc to the O-2 position of the terminal mannose residue in the a1 → 3 
branch of the Man5GlcNAc2 oligosaccharide. Subsequently, removal of two more 
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mannose residues from the a1→6 branch gives rise to a GlcNAcMan3GlcNAc2 
oligosaccharide. Before translocating to the trans-Golgi, N- 
acetylglucosaminyltransferase–II (GnT-II) mediates the transfer of an additional 
GlcNAc to the newly generated terminal mannose residue at the O-2 position in the 
a1→6 branch to form the conserved biantennary core structure 
GlcNAc2Man3GlcNAc2 39. In the trans-Golgi, the addition of Gal, bisecting GlcNAc, 
sialic acid (either NANA or NGNA) and core Fuc residues occurs via enzymatic 
addition by specific transferases using nucleotide-charged monosaccharide donors. 
Figure 1.3 summarizes the major steps of N-linked glycan biosynthesis. Specific 
glycosylation patterns are associated with different effector functions. For instance, 
high mannose variants (Man5/8/9) would also lack core Fuc, resulting in higher 
binding affinity to FcRIIIa and enhanced ADCC activity.  
                                                                                                                                               11  
 
 Figure 1.2: Major N-linked glycoforms of mAb therapeutics 32.    
.  
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Figure 1.3: Antibody N-linked glycan biosynthesis pathways. Schematic presentation 
is based on the work of Kornfeld and Kornfeld 39.  
  
1.5 Click chemistry  
Click chemistry is a method for attaching a probe or substrate to a specific biomolecule, 
a process called bioconjugation. A fluorophore or reporter molecule can be attached 
via click chemistry and this has made it a powerful tool for identifying, locating, and 
characterizing both old and new biomolecules. The classic 42 click reaction is formation 
of a 5-membered heteroatom atom ring by azide and alkyne in presence of copper: a 
Cu(I)-catalyzed azide alkyne cycloaddition (CuAAC).  
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However, the use of the copper-catalyzed azide–alkyne cycloaddition (CuAAC) was 
severely compromised in the context of biological matter, due to the toxicity of the 
inevitable copper(I)species to living cells and organisms.  With the clever insight by 
researchers at the University of California, Berkeley 43 who came up with  strain-
promoted azide alkyne cycloaddition (SPAAC) of cyclooctynes with azides is a highly 
versatile copper-free version of the popular click reaction 4445. This is an efficient and 
clean bioconjugation tool and the usefulness of cyclooctyne–azide cycloaddition is now 
adopted in a wide range of fields of chemical science and beyond. Its ease of operation, 
broad solvent compatibility, 100 % atom efficiency, and the high stability of the 
resulting triazole product, just to name a few aspects, have catapulted this so-called 
strainpromoted azide–alkyne cycloaddition (SPAAC) right into the top-shelf of the 
toolbox of chemical biologists, material scientists, biotechnologists, medicinal 
chemists, and more.  
1.6. Antibodies as Therapeutics  
  
With the advent of advanced hybridoma techniques and phage display, 
antibodies are being investigated for several different applications in research and in 
the clinic. In research, antibodies have become an indispensable reagent for various 
experimental techniques. However, for the purpose of this thesis, clinical application 
of antibodies is the focus. Antibodies in the clinic have been utilized in versatile 
applications including, but not limited to, antibody-drug conjugates, diagnostic agents, 
targeting ligands and as therapeutics themselves. Here we will focus on the two classes 
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that have been used as therapeutics for cancer therapy, antibody-drug conjugates and 
antibody conjugated nanoparticles.  
  
1.6.1. Antibody Drug Conjugates (ADCs)  
  
ADCs are a special class of therapeutics that have gained significant attention 
in the past decade. The idea behind ADCs is to specifically deliver cytotoxic drugs to 
the tumor by leveraging a key property of antibodies i.e. specificity, and in turn sparing 
normal cells of toxicity. ADCs consist of a monoclonal antibody conjugated, via a 
linker, to an extremely potent drug.  
Currently, there are six FDA approved ADCs, including brentuximab vedotin 
(AdcetrisÒ) 46 for the treatment of CD30 positive Hodgkin’s lymphoma, ado-
trastuzumab emtansine (KadcyclaÒ) 47 for the treatment of HER2 positive breast 
cancer, gemtuzumab ozogamicin (MylotargÒ) 48 for the treatment of CD33 positive 
acute myeloid leukemia, inotuzumab ozogamicin (BesponsaÒ) 49 for the treatment of 
CD22 positive acute lymphoblastic leukemia, moxetumomab pasudotox (LumoxitiÒ) 
50 for relapsed or refractory haircell leukemia (HCL) and polatuzumab vendotinpiiq 
(PolivyÒ) 51 for diffused large B cell lymphoma  (DLBCL).  
Mechanism of action of ADC: When designing an ideal ADC, it is essential to 
understand the mechanism of action in order to identify the desired features of each of 
its three components. An ideal ADC is one that retains the selectivity of a mAb while 
still being able to release the cytotoxic drug in quantities large enough to kill tumors 
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cells. Each of the steps involved in the mechanism of action is associated with unique 
challenges that complicate the design of ADCs 52. These are illustrated in Figure 1.4. 
ADCs are administered intravenously in order to prevent the mAb from being 
destroyed by gastric acids and proteolytic enzymes. The mAb component of the ADC 
enables it to circulate in the bloodstream until it finds and binds to tumor cell -specific 
surface antigens or tumor microenvironment-associated targets. In the interest of 
preventing unwarranted release of the cytotoxin and maximizing drug delivery to 
cancer cells, an ideal linker would not only have to be stable in the bloodstream but 
also capable of releasing the active form of the  
 
Figure 1.4: Mechanism of action of ADC53   
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cytotoxic drug when required 54. Once the mAb component of the ADC is bound to its 
target antigen, the ADC–antigen complex should theoretically be internalized via 
receptor-mediated endocytosis. The internalization process finishes with the formation 
of a clathrin coated early endosome containing the ADC–antigen complex 55. An 
influx of H+ ions into the endosome results in an acidic environment that facilitates 
the interaction between the mAb component of a fraction of ADCs and human 
neonatal Fc receptors (FcRns). The bound ADCs are transported outside the cell, 
where the physiological pH of 7.4 enables the release of the ADC from the FcRn 56. 
This mechanism acts as a buffer for preventing the death of healthy cells in the case 
of ADC mis-delivery. Excessive binding of ADCs to tumor cell FcRns might however 
restrict the release of the cytotoxic drug and prevent the ADC from taking effect 57. 
FcRn expression is primarily within the endosomes of endothelial cells. ADCs that 
remain in the endosome without binding to FcRn receptors form the late endosome. 
These subsequently undergo lysosomal degradation, allowing the release of the 
cytotoxic drug into the cytoplasm. At this stage, it is crucial to ensure that a sufficient 
(i.e. threshold) concentration of the drug is present within the cancer cell for its 
destruction to be guaranteed. This is however complicated in practice by the facts that 
cell-surface antigens are often quite limited and the process of internalization rather 
inefficient 58. Assuming all the steps involved in the mechanism of ADC action have 
an efficiency of 50%, only 1%–2% of the administered drug will reach tumor cells 59. 
This makes the choice of cytotoxin particularly important, as it is required to be highly 
efficacious at very low concentrations. Drugs that are usually unsuitable for normal 
chemotherapy (due to excessive toxicity) are therefore a necessary component of 
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ADCs. Different classes of cytotoxic drugs result in cell death using various 
mechanisms 53. The common element between all the classes is interference with 
critical cell functioning and, as a consequence, either direct killing of the cell or 
induction of apoptosis. As targeted cancer cells die, there is potential for the active 
cytotoxic drug to kill neighboring tumor cells and the supporting stromal tissue. The 
design of ADCs with respect to the choice of target, mAb, linker and cytotoxin are all 
very important determinants of whether or not the threshold concentration of the 
cytotoxic drug is reached within the tumor cell. These factors therefore determine the 
overall success of an ADC.  
Key Components of ADC: ADCs have three components: antibody, linker and drug. 
The antibody should be specific for a cell surface target molecule that is selectively 
expressed on cancer cells, or overexpressed on cancer cells relative to normal cells 60. 
The payload of an ADC must be highly cytotoxic so that it can kill tumor cells at the 
intracellular concentrations achievable following distribution of the ADC into tumor 
tissue, and because only a limited number of drug molecules can be linked to an 
antibody molecule (typically, an average of 3–4 per antibody) without severely 
compromising its biophysical and pharmacokinetic properties 60–62. Indeed, the 
breakthrough in ADC research that eventually led to the creation of approved and 
marketed products came with the realization that the cytotoxic agents suitable for ADC 
approaches need to have potency in the picomolar range to be able to be delivered in 
sufficient quantity to enough cancer cells to effect a therapeutic benefit 60–62. The 
cytotoxic compounds used in approved and marketed ADCs are derivatives of 
calicheamicin, a class of highly cytotoxic enediyne antibiotics which kill cells by 
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causing DNA double-strand breaks 60,63, and derivatives of the potent antimitotic 
microtubule- 
disrupting agents, dolastatin 10 (auristatins) 61,64 and maytansine 62,65,66. The third vital 
component of an ADC is the linker that forms a chemical connection between the 
payload and the antibody. The linker should be sufficiently stable in circulation to 
allow the payload to remain attached to the antibody while in circulation as it 
distributes into tissues (including solid tumor tissue), yet should allow efficient release 
of an active cell-killing agent once the ADC is taken up into the cancer cells 60. Linkers 
can be characterized as either cleavable, where a chemical bond (or bonds) between 
the payload and the attachment site on the antibody (usually an amino acid) can be 
cleaved intracellularly 67,68, or as non-cleavable, where the final active metabolite 
released within the cell includes the payload and all elements of the linker still attached 
to an amino acid residue of the antibody, typically a lysine or a cysteine residue, 
following complete proteolytic degradation of the ADC within the lysosome of the 
cell 69–72.   
The design goal for an ADC is to harness the potent tumor cell-killing action of the 
payload, while retaining the favorable in vivo pharmacokinetic and biodistribution 
properties of the immunoglobulin, as well as any intrinsic biologic or immunologic 
activity it may have 60,62,69–72. Much of the selection of the optimal antibody, the ideal 
linker–payload chemistry, and the optimal number of payload molecules linked per 
antibody molecule, are determined empirically, with a focus on maximizing the  
therapeutic index of the ADC 60,72.  
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1.6.2. Antibody conjugated nanoparticles  
Nanomedicine has gained significant importance in cancer therapy over the past 
few years. The primary advantage of nanoparticles is their size range (1 to 500 nm) 
due to which they are internalized into cells better than larger sized delivery systems 
such as microparticles 73. This is essential for chemotherapeutic drugs such as 
paclitaxel that act intracellularly. The surface properties of nanoparticles can be 
modified to be hydrophobic or hydrophilic depending upon the requirement. Further, 
a drug loaded in nanoparticles remains protected for longer, and nanoparticles can be 
formulated to act as a controlled release reservoir for the drug. Nanoparticles have also 
been engineered for targeted drug delivery to avoid toxicity and improve efficacy 74. 
Nanoparticles also have a unique passive targeting feature in case of cancer therapy.  
In normal tissues, the blood vessels are lined by tightly packed endothelial cells that 
are highly selective in terms of what moves out of the lumen into the interstitial fluid. 
As opposed to this, in case of tumors, the vasculature is leaky and pores between 
endothelial cells are abnormally large 75. This is due to rapid and incomplete 
development of the tumor vasculature. Additionally, the tumor vasculature has a 
missing layer of pericytes surrounding the vessels. This uniquely leaky vasculature of 
the tumor allows nanoparticles to preferentially “leak” out of the blood vessels and 
move into the tumor interstitial fluid. This would not be possible in case of other 
organs due to the tight endothelial junctions, liver being the exception.   
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Under normal conditions, fluid draining from the blood vessels into tissue is cleared 
via the lymphatic system. However, tumors lack an efficient lymphatic system, as a 
result of which, there is elevated interstitial fluid pressure (IFP) 76. Thus, the 
nanoparticles move into the tumor relatively easily and are unable to move out. This 
phenomenon of preferential uptake of nanoparticles followed by prolonged retention 
in the tumor is termed as the “Enhanced Permeability and Retention” effect or the EPR 
effect 77.   
 
Figure 1.5 Enhanced permeation and retention effect78  
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Although the EPR effect has been of the main driving force for the development of 
cancer nanotherapeutics, it is important to recognize that the EPR effect is not a 
universal phenomenon.  
Not all tumor vessels are leaky to the same extent, not all pores are of uniform size, 
and thus, not all tumors exhibit the EPR effect.  
An extension of the EPR effect is active targeting. Actively targeted drug delivery 
involves the use of specific ligands that are able to recognize antigens or proteins that 
are overexpressed by the tumor. The ligands used for active targeting generally involve 
proteins, the most popular being antibodies and their fragments. In vivo stability, 
availability of different forms of antibodies (scFv, Fab fragment, dimers, whole 
antibody), and the availability of a myriad of techniques for antibody engineering 
makes them highly amenable for use in targeted drug delivery. Active targeting 
enables nanoparticles to “actively” bind to the cell surface and undergo receptor 
mediated internalization 74. Not only does active targeting provide the carrier with 
additional means for endocytosis, but also a target to “hold on” to in the tumor, 
resulting in improved retention. Recent reports have pointed out that the main 
advantage of actively targeted nanoparticles is the improved internalization of 
nanoparticles, however the overall biodistribution remains unchanged 79,80. Targeted 
drug delivery (active or passive) has the potential to reduce the toxicity associated with 
the drug and improve its overall efficacy.  
Poly(DL-lactide-co-glycolide) (PLGA), an FDA approved polymer, has been one 
of the most commonly employed polymers in controlled release formulations and 
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tissue engineering applications due its safety, acceptable toxicity profile, 
biocompatibility and biodegradability 81. PLGA is degraded in vivo by hydrolysis into 
biologically compatible lactic acid and glycolic acid, both of which are eliminated 
from the body via the tricarboxylic acid (TCA) cycle. Drug release from PLGA matrix 
takes place initially by simple diffusion, followed by a combination of drug diffusion 
and polymer degradation. The rate of drug release from PLGA matrices can be 
customized by varying the lactide to glycolide ratio and the molecular weight of the 
polymer 82. Additionally, PLGA nanoparticles have been observed to escape endo-
lysosomal degradation via a pH dependent charge reversal, prolonging their half-life 
within the cell 83. Based on these desirable properties, we used PLGA to formulate 
nanoparticles in our studies.   
Despite its several advantages, PLGA still faces the most common pharmacokinetic 
problem observed with nanoparticles – rapid clearance by the mononuclear phagocytic 
system (MPS) 84. Once nanoparticles are injected into the bloodstream, they are almost 
instantly covered by opsonins that tag them as “foreign” for phagocytosis by 
macrophages. This results in rapid clearance of nanoparticles from the bloodstream, 
preventing them from reaching the site of action. In order to overcome this issue, 
multiple solutions have been tried, but by far the most successful and most popular is 
termed as ‘PEGylation’. PEGylation involves the introduction of poly(ethylene 
glycol) or PEG chains on the surface of nanoparticles. Presence of the PEG layer forms 
a hydrophilic barrier, reducing adsorption of opsonins. This allows nanoparticles to 
remain “hidden” from the MPS, significantly extending their circulation half-life 85.   
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Our lab uses the emulsion-solvent evaporation process for nanoparticles synthesis. 
In brief, this involves formulation of an oil-in-water emulsion with the polymer 
dissolved in the oil phase (organic solvent), followed by evaporation of the oil phase 
to form solid nanoparticles. An earlier publication from our lab describes the 
introduction of surface functional groups on nanoparticles by Interfacial Activity 
Assisted Surface Functionalization (IAASF) 86. This particular method is applicable 
to the solvent-emulsion evaporation technique of nanoparticle formulation. After the 
oil-in-water emulsion is formed, if a diblock co-polymer is introduced into the 
emulsion, its hydrophobic portion will align within the oil phase while the hydrophilic 
portion will align in the water phase. This expected orientation can be utilized to our 
advantage by the introduction of the required functional group on the hydrophilic 
portion of the polymer that will align outwards. We used IAASF for the introduction 
of PEG with terminal DBCO groups on the nanoparticle surface. These DBCO 
functional groups were then used to functionalize nanoparticles with  
glycoengineered antibodies via copper-free click chemistry.  
1.7. Current approaches in antibody conjugation and 
challenges  
  
 As in the previous section we have seen that therapeutic activity of an antibody can 
also be improved by conjugating it to a cytotoxic payload directly or to a moiety loaded 
with cytotoxic payload. There are many chemical, enzymatic and chemoenzymatic 
methods used to modify the antibody for conjugation.  
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  Interchain disulfide bridges and surface-exposed lysines are the most currently used 
residues on the antibody for conjugation, respectively (>50 vs. >30%) 87. 
Theoretically, the linkage of cytotoxic payloads to the surface-exposed lysine of mAb 
occurs after reduction of 40 lysine residues on both heavy and light chain of mAb 
and it results in 0–8 cytotoxic payload linkages per antibody and heterogeneity with 
about one million different antibody conjugated species 60,67,88. Cysteine conjugation 
occurs after reduction of four interchain disulfide bonds and results in eight exposed 
sulfhydryl groups. Linking payload per antibody can differ from zero to 8 molecules, 
generating a heterogeneous population of antibody conjugated species  (Greater than 
one hundred different species). It is possible to reduce just two of four interchain 
mAb’s disulfide bonds of cysteine residues through carefully mild reduction 
conditions, as interchain disulfide bridges are  
more prone to reduction than intrachain disulfide bridges 17,31,89–91. However, such 
mild reduction  
is not easily possible in practice and a diverse number of cysteines may be reduced (0–
4), resulting in a heterogeneous mixture 87,88.  
Due to low stability and safety properties of the pharmaceutical products with 
heterogeneous contents, they are complex to be accurately predicted in terms of 
efficacy or therapeutic window 87,92. Therefore, improvement of conjugation 
methods to achieve homogeneous product is very crucial.  
Recently, site-specific enzyme-mediated and chemoenzymatic site direct 
conjugation was established to overcome the above mentioned limitation. This site-
specific enzyme-mediated conjugation involves incorporating a thiolated sugar 
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analogue, 6-thiofucose, to the antibody carbohydrate that introduces new chemically 
active thiol groups using fucosyltransferase 29,90,91. Chemoenzymatic site direct 
conjugation, involves  introducing two azide groups at asparagine 297 (Asn-297) 
residue in antibody constant region (Fc) is linked with cytotoxic payloads using 
coppermediated click reaction . The azide functional groups are formed in a selective 
hydrolysis reaction that is mediated by an Endo-beta-N-acetylglucosaminidase 
(EndoS) chemoenzyme 87,89,91. However, using copper as a catalyst which is toxic to 
biological system and post production modification can often result in reduced affinity 
of the antibody towards the target antigen 92.  
1.8. Statement of problem and Specific Aims   
Current approaches to antibody-based syntheses involve chemical and enzymatic 
modifications of pre-formed antibodies 29,90,91. Such reactions can affect the antigen-
affinity and pharmacokinetics of the antibody 92. The central objective of this thesis is to 
advance a new antibody glycoengineering technology that will allow for facile synthesis 
of antibody-based drug delivery systems. The work presented here examines the use of 
glycoengineered antibodies for the development of antibody drug conjugates and antibody 
functionalized polymeric nanoparticles. The specific aims of this research were:  
1.8.1. Specific Aim 1: Generation of glycoengineered antibodies   
Our work in chapter 2 focused on the development of glycoengineered antibodies. We 
developed glycoengineered anti-perlecan antibody as well as glycoengineered anti-CD133 
antibody. These antibodies were characterized and quantified for the presence of azide 
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groups. Additionally, we compared the antigen binding affinity and tumor accumulation 
of glycoengineered antibodies.  
1.8.2. Specific Aim 2: Synthesis of ADC with glycoengineered anti-
perlecan antibody   
In chapter 3, we synthesized an ADC using the glycoengineered anti-perlecan 
antibody developed in chapter 2. We characterized the ADC for drug loading and carried 
out in vivo and in vitro studies to determine its therapeutic efficacy in a mouse model of 
triple negative breast cancer.  
1.8.3. Specific Aim 3: Synthesis of antibody conjugated 
nanoparticles with glycoengineered anti-perlecan antibody   
In chapter 4, we synthesized antibody conjugated nanoparticles using the 
glycoengineered antiperlecan antibody developed in chapter 2. We encapsulated 
paclitaxel in nanoparticles and surface functionalized the nanoparticles with anti-perlecan 
antibody to form antibody conjugated nanoparticles. We determine the in vivo and in vitro 
therapeutic efficacy of these targeted nanoparticles in mouse models of triple negative 
breast cancer and non-muscle invasive bladder cancer.  
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Chapter 2: Development of 
glycoengineered antibody   
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2.1 Introduction  
  Therapeutic mAbs have an asparagine (Asn)-X-Ser/Thr (where X is any amino 
acid except a Pro) consensus sequence for N-glycosylation at position Asn297 in the 
constant domain of the heavy chain 7. The N-linked glycans of human IgGs are 
typically biantennary complex structures. This conserved core structure is composed 
of two N-acetylglucosamine (GlcNAc), three mannose, and two GlcNAc residues that 
are b-1, 2 linked to a-6 mannose and a-3 mannose, forming two antennae. Additional 
monosaccharides extended from the core may be present. Depending on the host 
glycosylation machinery, additional fucose (Fuc), galactose (Gal), sialic acid, may be 
added to the core 32.  
Alteration of glycan compositions and structures can cause conformational changes 
of the Fc domain, which could change binding affinity to Fc receptors, resulting in 
changes to immune effector functions 36. Fc effector functions include complement-
dependent cytotoxicity (CDC), antibody dependent cell-mediated cytotoxicity 
(ADCC), and antibody dependent cell-mediated phagocytosis (ADCP) 35,92.  
Previous studies have examined the use of N-linked glycans to conjugate 
therapeutic agents to mAbs. A number of studies have utilized chemoenzymatic 
technologies to modify the N-glycans 92. However, such postproduction modification 
can often result in reduced affinity of the antibody towards target antigen. In this 
chapter, we report a unique glycoengineering strategy, which allows for substitution of 
one or all of N-glycan sugars with non-natural sugars containing a reactive group 
during the production of the antibody. This strategy can then be used for site specific 
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conjugation of a payload. As this involves metabolic engineering of the antibody in the 
constant region, target binding affinity is expected to remain unaffected.   
We used azide as our reactive group for two main reasons. First, as azide groups 
are not found in the living system 93, glycoengineering will be the only process through 
which they will be incorporated in the antibody. Second, the azide groups can be used 
to easily conjugate a payload with a cyclooctyne group via strain-promoted alkyne-
azide cycloaddition also called as copperfree click chemistry 43. In our studies, we used 
N-azidoacetylgalactosamine-tetraacylated (Ac4GalNAz) as the non-natural sugar to 
incorporate azide groups in two different antibodies. The effect of introducing the non-
natural sugar on in vitro antigen affinity and in vivo tumor accumulation were 
determined.      
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2.2 Methods  
2.2.1 Materials  
Cell culture supplies were obtained from Invitrogen (Waltham, MA) or Corning 
(Tewksbury, MA), unless otherwise specified. Fetal bovine serum (FBS) was 
purchased from Atlanta Biologicals (Flowery Branch, GA). Control isotype IgG (Cat. 
No. 401114) was purchased from Calbiochem (Billerica, MA). The materials for 
SDS/PAGE were obtained from Bio-Rad (Hercules, CA). N-
azidoacetylgalactosamine-tetraacylated (Ac4GalNAz) sugar, 
DBCOcarboxyrhodamine dye and DBCO-PEG4-biotin were purchased from Click 
Chemistry Tools (Scottsdale, AZ). Deionized (DI) water was available through 
university resources. 
2.2.2 Cell Culture  
MDA-MB-231-LM2 cells were from Joan Massague Laboraotry and have been 
previously described as being derived from lung metastasis arising from parental 
MDA-MB-231 tumors in mice. Cells between passages of 2 and 10 were used for all 
the studies. Cells were cultured in minimum essential medium (MEM) with 10% v/v 
fetal bovine serum (FBS) and 1% v/v penicillin/streptomycin in a humidified 
atmosphere with 5% CO2. Caco2 cells (a continuous line of heterogeneous human 
epithelial colorectal adenocarcinoma cells) were obtained from ATCC. Cells were 
cultured in eagles minimum essential medium (EMEM) with 20% v/v fetal bovine 
                                                                                                                                               31  
serum (FBS) and 1% v/v penicillin/streptomycin in a humidified atmosphere with 5% 
CO2.  
2.2.3 Preparation and purification of glycoengineered antibodies  
  
2.2.3.1 Glycoengineered anti-perlecan antibody  
Expi293F Expression System by Life Technologies (Carlsbad, CA) was used for 
the expression of anti-perlecan antibodies. During the process of production of 
antibody, 25 μM of Ac4GalNAz sugar was added to the cells with the enhancers a day 
after transfection and also for subsequent three days. Control antibody was made 
without the addition of Ac4GalNAz sugar. Seven days after transfection, affinity 
purification of antibodies was carried out using Protein A Plus (Pierce, Rockford, IL) 
followed by buffer exchange into tris-buffered saline containing 5mM EDTA. ZebaTM 
Spin Desalting Columns (87769, Pierce Biotechnology, Rockford, IL) were used for 
the buffer exchange step. Antibody stocks were stored at -20°C in single use aliquots 
until use. Once thawed, the samples were placed at 4°C for short-term storage. Quality 
control evaluation involved resolution via SDS/PAGE for reduced and nonreduced 
samples and flow cytometry for confirmation of binding affinity.  
2.2.3.2 Glycoengineered anti-CD133 antibody  
CD133 hybridoma cells 94 were used for the expression of anti-CD133 antibodies. 
During the process of growing hybridoma cells, when the cells reached 60% 
confluency,  25μM of Ac4GalNAz sugar was added to the cells for subsequent three 
days. Control antibody was made without the addition of Ac4GalNAz sugar to 
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hybridoma cells. After five days, purification of antibody was carried out by using 
AmiconÒ Ultra-15 Centrifugal filter units, 100KDa (Millipore Sigma, Burlington, 
MA). ZebaTM Spin Desalting Columns (87769, Pierce Biotechnology, Rockford, IL) 
were used for the buffer exchange into tris-buffered saline containing 5mM EDTA. 
Antibody stocks were stored at -20°C in single use aliquots until use.  
Once thawed, the samples were placed at 4°C for short-term storage. Quality 
control evaluation involved resolution via SDS/PAGE for reduced and non-reduced 
samples and flow cytometry for confirmation of binding affinity.  
2.2.4 Fluorophore binding to glycoengineered antibody  
DBCO-carboxyrhodamine was used to label the glycoengineered antibody. 
Fluorophore was incubated with the antibody at 37°C for 2hrs on a rotating platform 
(Barnstead International, Dubuque, IA). Unbound dye was removed by dye removal 
columns (Pierce, Rockford, IL). This process was carried out using both control and 
glycoengineered antibodies. Flow cytometry was used to confirm the binding of 
fluorophore to antibody. For flow cytometry, fluorophore conjugated, anti-perlecan 
antibodies were incubated with MDA-MB-231-LM2 cells and anti-CD133 antibodies 
were incubated with Caco2 cells at a concentration of 100 nM for 2 hours at 4°C on a 
rotating platform, followed by three washes using FACS Buffer. The cells were re-
suspended in flow buffer and placed on ice until analysis by flow cytometry (BD 
LSRFortessa).  
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2.2.5 Biotin binding to glycoengineered antibody  
DBCO-PEG4-biotin was incubated with the antibody at 37°C for 2hrs on a rotating 
platform. Unbound DBCO-PEG4-biotin was removed by AmiconÒ Ultra-4 
Centrifugal filter units, 10KDa (Millipore Sigma, Burlington, MA). This process was 
carried out using both control and glycoengineered antibodies. Flow cytometry was 
used to confirm the binding of DBCOPEG4-biotin to the antibody. For flow cytometry, 
biotin conjugated, anti-perlecan antibodies were incubated with MDA-MB-231-LM2 
cells and anti-CD133 antibodies were incubated with  
Caco2 cells at a concentration of 100 nM for 1 hour at 4°C on a rotating platform, 
followed by three washes using FACS Buffer. Alexa Fluro 488 streptavidin (Life 
Technologies, Carlsbad, CA) was added to the cells and incubated at 4°C on a rotating 
platform, followed by three washes using FACS Buffer. The cells were re-suspended 
in flow buffer and placed on ice until analysis by flow cytometry. Biotin quantification 
kit (ThermoFisher Scientific) was used for quantification of number of biotin molecules 
conjugated per antibody.  
2.2.6 Binding affinity of glycoengineered antibody  
Flow cytometry was used to compare the binding affinity of glycoengineered 
antibody to that of control antibody. Anti-perlecan antibodies were incubated with 
MDA-MB-231-LM2 cells and anti-CD133 antibodies were incubated with Caco2 cells 
at a concentration of 100 nM for 1 hour at 4°C on a rotating platform, followed by three 
washes using FACS Buffer. Alexa Fluro 647 goat anti-human secondary antibody (Life 
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Technologies) was added and cells were incubated at 4°C on a rotating platform, 
followed by three washes using FACS Buffer. The cells were re-suspended in flow 
buffer and placed on ice until analysis by flow cytometry.   
2.2.7 Tumor accumulation of glycoengineered antibody  
This study was performed with anti-perlecan antibodies. Mice bearing MDA-MB-
231-LM2 tumors (~300 mm3) were injected with 100 μg of labeled isotype IgG control, 
anti-perlecan antibody (AM6 Ab) or glycoengineered anti-perlecan antibody (AM6-Az 
Ab) (n=3). Isotype IgG and AM6 Ab were labeled with Cy7 maleimide (Click 
Chemistry Tools) using immunothiolation to introduce reactive thiols onto the 
antibody. AM6-Az Ab was labelled with DNCO-Cy7 (Click Chemistry Tools, 
Arizona) using click chemistry. Mice were imaged using the IVIS Spectrum In Vivo 
Imaging System (University of Minnesota Imaging Centre) at various time intervals 
over 120 hours using excitation and emission filters of 750 nm and 775 nm, 
respectively. Data was acquired and analyzed using Living Image software. Data was 
tested for statistical significance using two way ANOVA, with multiple comparison 
post-hoc tests.   
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2.3 Results  
2.3.1 Glycoengineered antibody shows presence of azide  
To determine the presence of azide groups in glycoengineered antibodies, we 
incubated them with a fluorophore containing cyclooctyne group (DBCO-
carboxyrhodamine). Binding of the dye conjugated antibodies to the target tumor cells 
was evaluated by flow cytometry. For anti-perlecan antibody, fluorescent signals were 
only observed in cells incubated with AM6-Az Ab. Cells incubated with AM6 Ab had 
signal similar to that of control cells (Figure 2.1 A).  Similarly, for anti-CD133 antibody 
fluorescent signals were only observed in cells incubated with anti-CD133Az Ab and 
this signal was similar to the cells treated with commercial anti-CD133 Ab (Figure 2.1 
B). Cells incubated with anti-CD133 Ab had signal similar to control cells (Figure 2.1 
B).  
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Figure 2.1: Dye labelled antibody binding to cells. (A) Histogram depicting flow 
cytometry data of anti-perlecan antibody in MDA-MB-231-LM2 cells. 
Glycoengineered anti-perlecan antibody showed fluorescent signals upon binding to 
cells. (B) Histogram depicting flow cytometry data of anti-CD133 antibody in Caco2 
cells. Glycoengineered anti-CD133 antibody showed fluorescent signals upon binding 
to cells.  
2.3.2 Quantification for number of azide groups  
To quantify the number of azide groups per antibody, an indirect approach was 
used. We conjugated the glycoengineered antibody with DBCO-PEG4-biotin and then 
quantified the number of biotin molecules added to the antibody. After the conjugation 
of DBCO-PEG4-biotin to the antibodies, we first confirmed the presence of biotin by 
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flow cytometry using Alexa Fluro 488 streptavidin. For anti-perlecan antibody, 
fluorescent signal from streptavidin was only observed in cells incubated with AM6-
Az Ab. Cells incubated with AM6 Ab had signal similar to control cells (Figure 2.2 
A).  Similarly, for anti-CD133 antibody, fluorescent signals were only observed in 
cells incubated with anti-CD133-Az Ab whereas cells incubated with anti-CD133 Ab 
had signal similar to control cells (Figure 2.2 B).  
 
Figure 2.2: Biotinylated antibody binding to cells. (A) Histogram depicting flow 
cytometry data of anti-perlecan antibody in MDA-MB-231-LM2 cells. 
Glycoengineered anti-perlecan antibody showed presence of biotin. (B) Histogram 
depicting flow cytometry data of anti-CD133 antibody in Caco2 cells. Glycoengineered 
anti-CD133 antibody showed presence of biotin.  
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The biotinylated antibody was also used to quantify the number of biotin molecules 
per antibody by using biotin quantification kit. AM6-Az was found to contain 2.74 
biotin molecules per antibody molecule while anti-CD133-Az antibody was labeled 
with 1.44 biotin molecules per antibody molecule. The number of biotin molecules 
present on each antibody molecule depends on the number of available azide groups, 
and so these parameters can be directly correlated. So, on an average, AM6-Az Ab had 
~3 available azide groups per antibody and anti-CD133 Ab had ~2 available azide 
groups per antibody.  
2.3.3 Glycoengineering does not affect binding affinity  
  To determine whether glycoengineering and conjugation to a payload affects the 
antigen binding affinity, we first stained the cells with glycoengineered biotinylated 
antibody or control unmodified antibody, followed by staining with a secondary 
antibody. For anti-perlecan antibody, fluorescent signals from the secondary antibody 
were similar for both biotinylated AM6-Az antibody or the unmodified AM6 Ab 
(Figure 2.3 A). Similarly, for anti-CD133 antibody, fluorescent signals from the 
secondary antibody were similar for biotinylated anti-CD133-Az, commercial anti-
CD133 and anti-CD133 Ab (Figure 2.3 B). These results indicated that 
glycoengineering and conjugation of a payload does not affect the binding affinity of 
either of these antibodies for their respective target antigen.  
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Figure 2.3: Binding affinity of antibody. (A) Histogram depicting flow cytometry 
data of antiperlecan antibody in MDA-MB-231-LM2 cells. Glycoengineered anti-
perlecan and anti-perlecan antibody shows similar binding to cells. (B) Histogram 
depicting flow cytometry data of antiCD133 antibody in Caco2 cells. Glycoengineered 
anti-CD133, commercial anti-CD133 and antiCD133 antibody shows similar binding 
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2.3.4 Glycoengineered antibody accumulates in tumor  
Previous studies in our lab have shown that anti-perlecan antibody specifically 
accumulates in xenografted MDA-MB-231 tumors. We determined whether 
glycoengineered anti-perlecan antibody demonstrated similarly enhanced tumor 
accumulation. An imaging study was carried out in tumor-bearing mice with 
fluorescently labeled glycoengineered and control AM6 antibodies. Following IV 
administration, significant accumulation of the fluorescent signal could be observed in 
the tumor starting at 24 hours. Quantitative analysis of fluorescence in the tumors 
revealed a 34 fold higher accumulation for both AM6-Az and AM6 Ab versus the 
isotype IgG control (P<0.05 at 3-24 hours, p<0.001 at 36-120 hour, two-way ANOVA 
with multiple comparisons) (Figure 2.4), This enhancement in tumor accumulation is 
similar to reports testing other tumor-targeting antibodies 95,96. The Tmax in tumor for 
both AM6-Az and AM6 was 48 hours. This indicated that glycoengineered anti-
perlecan antibody also accumulates in the tumor similar to unmodified antiperlecan 
antibody.  
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Figure 2.4: Antibody targeting in vivo by fluorescence-based imaging. Quantified 
fluorescence values in tumor post antibody administration. AM6-Az and AM6 Ab 
accumulated between 3-4-fold higher concentrations in the tumor (***P<0.001, two-
way ANOVA with multiple comparisons, statistical significance is based on 
comparison between isotype IgG)    
 
2.4 Discussion  
The effector functions of monoclonal antibody are highly dependent on the 
structure of the Nlinked glycans in the Fc domain of the antibody and numerous 
investigations over past decades have evaluated methodologies to control the Fc glycan 
structures 7,94,97. These include core fucosylation, terminal galactosylation and 
sialylation, as well as introducing high-mannose and bisecting glycans via multiple 
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These glycans have also been modified to introduce new functional groups including 
azides using chemo-enzymatic reactions on already expressed antibodies 92.   
We hypothesized that substituting regular sugars in the cell culture medium with 
artificial sugars containing a reactive group is a simpler approach to change the 
glycoprofile of an antibody. After the production of glycoengineered antibodies, they 
were characterized for the presence of azide group by binding them to a fluorophore, 
DBCO-carboxyrhodamine. This fluorophore molecule consisted of a cyclooctyne 
group which will react with the azide molecule on the Nglycan of the glycoengineered 
antibody. The conjugation process was performed on control and glycoengineered 
antibody, but fluorescence signal was only seen from the cells treated with 
glycoengineered antibodies, indicating the presence of azide group.   
To quantify the number of azide groups introduced in each antibody molecule using 
the glycoengineering strategu, we conjugated the glycoengineered antibodies with 
DBCO-PEG4biotin molecule and then quantified the number of biotin molecules 
conjugated to the antibody. The number of biotin molecules conjugated to the antibody 
correlates to the number of azide molecules available for conjugation. Using this 
correlation, we found that on an average, antiperlecan antibody had 2-3 molecules of 
available azide groups per antibody and anti-CD133 antibody had 1-2 azide groups per 
antibody. It has been reported that attaching a biomolecule can affect the antigen 
binding affinity of antibody 98. So, we performed binding studies with the biotinylated 
antibodies and found no difference in binding affinity towards target antigen between 
control and glycoengineered antibodies. This indicates that glycoengineering and 
conjugation to a biomolecule does not affect the binding affinity towards target antigen.  
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It has been previously shown in our lab that anti-perlecan antibody accumulates in 
the tumor and in our studies, we found similar tumor accumulation of conventional and 
glycoengineered antibodies with Tmax of 48 hrs. Thus, the glycoengineering strategy 
can be used for incorporation of a reactive group on the antibody without affecting the 
tumor specificity of the antibody.   
By using azido sugars, we were able to exploit the high reactivity of azide groups 
to any biomolecule containing a cyclooctyne group. We glycoengineered antibodies 
produced by two different production systems i.e., anti-perlecan antibody produced 
using Expi293F Expression System and anti-CD133 antibody produced by hybridoma 
cells. Thus, our studies show that glycoengineering strategy can be used for different 
production systems and for different antibodies.  Additional optimization of this 
strategy may help in improving the number of available reactive groups per antibody.  
  
    
2.5 Conclusion  
A novel glycoengineering strategy was used to incorporate azide groups in the N-
glycan region of two different antibodies without affecting the antigen binding or in 
vivo tumor accumulation of the antibody. Cyclooctyne containing payloads including 
fluorophores and PEG conjugates were successfully conjugated to glycoengineered 
antibodies. These results suggest that the glycoengineering strategy advanced here 
could be used to synthesize antibody conjugates for therapeutic and diagnostic 
applications.   
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Chapter 3: Use of glycoengineered 
antiperlecan antibody for synthesis of 
antibodydrug conjugates (ADC)   
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3.1 Introduction  
 The number of available carrier-based drug systems for the treatment of cancer and 
other diseases have seen an exponential growth in the past three decades. In addition, 
within the past 20 years, the use and approval of monoclonal antibodies (mAbs) has 
risen sharply, both in the clinic as well as in development. While early mAb therapies 
were plagued with toxicities due to immunogenicity, modern genetic engineering has 
led to human/humanized antibodies that are approved today 99. Antibody–drug 
conjugates (ADCs) have emerged as the next generation anticancer therapeutic agents. 
ADCs harness the power of antibody specificity to target the delivery of highly potent 
drugs to the tumor site. Highly cytotoxic payloads are conjugated via linkers to tumor-
targeting antibodies with an expectation of improved efficacy, safety, and, therefore, 
the therapeutic window of the cytotoxic payload.   
Kadcyla and Adcetris are two FDA-approved ADCs that have shown remarkable 
clinical activities at well tolerated doses 100–102. Kadcyla targets HER2-positive breast 
cancer with a maytansinoid DM1 conjugate 103, while Adcetris targets CD30-positive 
Hodgkin lymphoma with a monomethyl auristatin E (MMAE) conjugate 104. A large 
number of other ADCs with various target antibodies, different linkers, and various 
payloads are now being tested in preclinical and clinical studies 105.  
Currently used approaches to introduce therapeutic payloads rely primarily on 
conjugation to either side-chain amine or carboxylic acid groups or conjugation to 
thiols 92. Because these reactions are not site-specific and not easily controlled, these 
chemistries can result in reduced affinity for the target antigen. Further, these 
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conjugation reactions lack selectivity and can result in heterogeneous mixtures of 
products that differ in the sites and stoichiometry of modification.  
In this chapter, we present the results of our studies examining the use of 
glycoengineering strategy to synthesize ADCs   
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3.2 Methods  
3.2.1 Materials  
Cell culture supplies were obtained from Invitrogen (Waltham, MA) or Corning 
(Tewksbury,  
MA), unless otherwise specified. Fetal bovine serum (FBS) was purchased from 
Atlanta Biologicals (Flowery Branch, GA). N-azidoacetylgalactosamine-tetraacylated 
(Ac4GalNAz) sugar and DBCO-PEG12-MMAE was purchased from Click Chemistry 
Tools (Scottsdale, AZ).  
Deionized (DI) water was available through university resources.  
3.2.2 Cell Culture  
MDA-MB-231-LM2 cells were from Joan Massague Laboraotry and have been 
previously described as being derived from lung metastasis arising from parental 
MDA-MB-231 tumors in mice. Cells between passages of 2 and 10 were used for all 
the studies. Cells were cultured in minimum essential medium (MEM) with 10% v/v 
fetal bovine serum (FBS) and 1% v/v penicillin/streptomycin in a humidified 
atmosphere with 5% CO2.   
3.2.3 Preparation and purification of glycoengineered anti-perlecan 
antibodies  
Expi293F Expression System by Life Technologies (Carlsbad, CA) was used for 
the expression of anti-perlecan antibodies. During the process of production of 
antibody, 25 μM of Ac4GalNAz sugar was added to the cells with the enhancers a day 
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after transfection and also for subsequent three days. Control antibody was made 
without the addition of Ac4GalNAz sugar.  
Seven days after transfection, affinity purification of antibodies was carried out using 
Protein A  
Plus (Pierce, Rockford, IL) followed by buffer exchange into tris-buffered saline 
containing 5mM EDTA. ZebaTM Spin Desalting Columns (87769, Pierce 
Biotechnology, Rockford, IL) were used for the buffer exchange step. Antibody stocks 
were stored at -20°C in single use aliquots until use. Once thawed, the samples were 
placed at 4°C for short-term storage. Quality control evaluation involved resolution 
via SDS/PAGE for reduced and non-reduced samples and flow cytometry for 
confirmation of binding affinity.  
3.2.4 Preparation, purification and characterization of ADC  
DBCO-PEG12-MMAE conjugated to glycoengineered anti-perlecan antibody by 
incubating the PEG-drug conjugate with the antibody at 4°C for 12 hrs on a rotating 
platform (Barnstead International, Dubuque, IA). Unbound Drug was removed by 
AmiconÒ Ultra-4 Centrifugal filter units, 10KDa (Millipore Sigma, Burlington, MA). 
ADC stocks were stored at -20°C in single use aliquots until use. Once thawed, the 
samples were placed at 4°C for short-term storage. Drug to antibody ratio (DAR) was 
determined by UV Vis spectroscopy using Nanodrop 2000c (ThermoFisher Scientific, 
Waltham, MA). This method was used as the UV/VIS spectra of the drug and of the 
antibody had different lmax values of 248 nm and 280 nm respectively 106. Using the 
measured absorbances of the ADC and the extinction coefficients of the mAb at its lmax 
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of ~280 nm and the drug at its lmax of 248 nm, the individual concentrations of mAb and 
drug were determined by solving two simultaneous equations. From this, the molar ratio 
(moles of drug per mole of antibody) was calculated. The following are the equations used 
for calculation of DAR 107:  
where,  
  ∈#$%)	, ∈#/$) = extinction coefficient of drug at 280 and 248nm  
 𝐴#$%	 𝐶-.𝑙  ∈#$%, ∈#/$ = extinction coefficient of antibody at 280 and 248nm  
𝐶 
  𝐴#/$	 𝐶-.𝑙 𝐶-.)	= = concentration of drug concentration of 
antibody    
𝑙 = Detector path length  
 𝑀𝑅	   𝑀𝑅	 = 𝐶)/𝐶-. = Drug:Ab 
molar ratio  
𝑅 = 𝐴#/$/𝐴#$% = Absorbance ratio  
3.2.4 Internalization of anti-perlecan antibody  
Internalization and intracellular distribution of anti-perlecan antibody was 
determined by confocal laser scanning microscopy (Olympus FluoView FV1000 BX2 
Upright Confocal,  
Olmpus, Center Valley, PA). MDA-MB-231-LM2 cells (10000/chamber) were seeded 
into a  
Lab-TekÒ Chamber SlideTM system (Sigma). The next day, the cells were 
incubated with AM6-Az Ab (100 nM) labelled with DBCO-Cy 5.5 for 6 or 24 hours 
and then rinsed with PBS twice. Cells were counterstained with LysoTrackerÒ 
Green (Thermo Scientific) and fixed with  
3% paraformaldehyde (PFA), followed by staining with 4’,6-diamidino-2-
phenylindole (DAPI; Thermo Scientific). Confocal images were further analyzed by 
Olympus Fluoview viewer 2.0 software.  
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3.2.5 Cytotoxicity study with ADC  
LM2 cells were seeded at 2500 cells per well in a 96-well plate and allowed to 
adhere overnight. Treatments (free MMAE, AM6 Ab or AM6-MMAE ADC) were 
added the next day at 125 nM equivalent MMAE concentration or 50 nM equivalent 
antibody concentration. The treatments were incubated for 6 hours, followed by 
removal of the treatments and addition of fresh media. Cell survival was analyzed at 
48 hours using CellTiter 96 AQueous One Solution Cell Proliferation Assay (Promega, 
Madison, WI).  
3.2.6 Tumor growth inhibition study  
MDA-MB-231-LM2 tumors were grafted in Balb/c homozygous nude mice (Jackson 
Labs). Once tumor volumes reached 100 mm3, three doses of of the ADC at 3 mg/kg or 
0.3 mg/kg were  
administered through tail vein injection once every 96 hrs. Saline and equivalent dose of 
free drug and  antibody (equivalent to 3mg/kg of ADC dose) were used as controls (n=7). 
Tumor volumes were measured every third day with digital Vernier calipers (Marathon 
Watch, Vaughn, Canada). Tumor volumes were calculated from the ellipsoid sphere 
equation V = (L2* W)/2, L being the longer measurement. Two way ANOVA, with 
multiple comparison post-tests, was used to determine the  
statistical significance of the data.  
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3.3 Results  
3.3.1 DAR of ADC  
The glycoengineered anti-perlecan antibody AM6 was conjugated to a highly 
potent drug molecule, MMAE. Our previous studies demonstrated that 
glycoengineered AM6 has 2-3 azide groups per antibody (Section 2.3). The ADC 
constructed here with MMAE was found to have 2.56 MMAE molecules per molecule 
of antibody. Thus, this correlates well with the number of azide groups available for 
conjugation. For studies described below, the concentrations of ADC are reported 
based on the antibody concentration.  
3.3.2 Anti-perlecan antibody shows slow internalization   
As explained in Section 1.6.1, internalization of the ADC is a key determinant of 
efficacy while using non-cleavable linker technology for ADC. Insufficient 
internalization can prevent the cytotoxin from reaching the threshold concentration 108. 
To confirm that the anti-perlecan antibody AM6 was indeed internalized by MDA-
MB-231-LM2 cells after binding to the target surface antigen, we performed confocal 
microscopy studies. Cells were incubated with antibody for 6 hours and 24 hours, fixed 
and imaged after staining with DAPI (blue) and lysotracker (green) to visualize the 
nucleus and acidic endo/lysosomes, respectively. A majority of antibody was localized 
on the cell membrane after 6 hours. After 24 hours, a small fraction of the antibody 
was still localized on the cell membrane; however, a majority of the antibody was 
internalized. Antibody associated fluorescence was observed in the endo/lysosomes 
(shown by the presence of yellow fluorescence in the merged picture) and in the 
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nucleus (shown by the presence of pink fluorescence in the merged picture) (Figure 
3.3). This data shows that anti-perlecan antibody is slowly internalized into cells.     
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Figure 3.1: Antibody internalization by confocal imaging. Blue: nucleus; Green: 
endo/lysosomes; red: anti-perlecan antibody. Scale bar, 5 um.  
3.3.3 ADC kills cancer cells more effectively  
In order to test the potency of the AM6-MMAE ADC, we first performed an in vitro 
cytotoxicity assay with MDA-MB-231-LM2 cells. At a concentration of 50 nM, treatment 
with ADC resulted in a significantly greater tumor cell kill as compared to that with an 
equivalent concentration of free MMAE (46% viability as opposed to 71% in case of 
MMAE, P<0.05, two way ANOVA with multiple comparison tests, Figure 3.1). We did 




Figure 3.2: In vitro cytotoxicity study with MDA-MB-231-LM2 cells. ADC treated 
groups showed higher cytotoxicity (*P<0.05, two way ANOVA with multiple comparison 
tests, statistical significance is based off comparison between control cells, AM6-Az Ab 
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3.3.4 ADC is effective in inhibiting tumor growth in vivo  
  In order to determine the ability of ADCs to improve drug delivery in vivo, we tested the 
anticancer efficacy in the MDA-MB-231-LM2 orthotopic mouse tumor model (Figure 
3.2). ADCs provide selective delivery of highly potent cytotoxic agent to cancer cells via 
specific binding of the antibody to cancer selective cell surface molecules 13. Based on 
improved cytotoxicity of ADC relative to that of free drug, we tested two concentrations 
of ADC in vivo. We observed improved tumor growth inhibition with 3 mg/kg of ADC 
relative to equivalent dose of MMAE and AM6-Az Ab (P<0.001, two-way ANOVA with 
multiple comparisons, statistical significance is based on comparison between untreated, 
MMAE and AM6-Az Ab on the last day of the study). On the other hand, 0.3 mg/kg ADC 
also showed tumor inhibition relative to MMAE and AM6-Az Ab (dose was equivalent 
to 3mg/kg of ADC) (P<0.05, two-way ANOVA with multiple comparisons, statistical 
significance is based on comparison between untreated, MMAE and AM6-Az Ab on the 
last day of the study). On day 26, the untreated animals had an average tumor volume of 
~1950 mm3. Free MMAE and AM6-Az Ab showed around 18% tumor inhibition. On the 
other hand, 0.3 mg/kg ADC dose showed 26% tumor inhibition while 3 mg/kg ADC dose 
showed 55% tumor inhibition relative to that of untreated control at the end of the study.  
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Figure 3.3: Efficacy study in Balb/c athymic nude mice. 3 mg/kg ADC showed 
significantly enhanced tumor inhibition over MMAE and AM6-Az Ab (**P<0.001, two-
way ANOVA with multiple comparisons, statistical significance is based on comparison 
between untreated, MMAE and AM6-Az Ab on the last day of the study). 0.3 mg/kg ADC 
also showed significantly tumor inhibition over MMAE and AM6-Az Ab (*P<0.05, two-
way ANOVA with multiple comparisons, statistical significance is based on comparison 
between untreated, MMAE and AM6-Az Ab on the last day of  
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3.4 Discussion  
  
Conjugation of drugs to antibodies has been performed through reactions with the 
activated carboxyl groups of N hydroxy succinimide (NHS) esters with lysine 
residues, or through the reactions of thiol-specific reagents, such as maleimide, with 
cysteines 109. Lysine conjugation results in 0–8 drug molecules per antibody, and 
peptide mapping has determined that conjugation occurs on both the heavy and light 
chains at about 20 different lysine residues (~40 lysine residues are present per mAb). 
Therefore, more than one million different ADC species can be generated through this 
reaction 29. For cysteine conjugation, the drug/antibody ratio (DAR) can range from 0 
to 8; thus, generating more than 100 different ADC species 91. However, several 
critical issues regarding the performance of ADCs prepared by the conventional 
methods are still being investigated. Several groups have reported that changing the 
number and position of the drug payload in the ADCs affects the pharmacokinetics, 
drug release rates, and biological activity 10,90.   
Our strategy for site-specific antibody drug conjugation technology involves 
coupling the drug molecules to modified N297 glycans on the antibody. This approach 
is expected to generate sitespecific ADCs. Although the DAR achieved with this 
approach was 2-3, we expect that this can be further optimized to increase the available 
reactive groups present on the N297 glycan of the antibody. The AM6-MMAE ADC 
showed better antitumor efficacy compared to the controls in vitro as well as in vivo. 
As discussed in Section 1.6.1, linker technology is a critical parameter affecting the 
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efficacy of any ADC. In our studies, we used a non-cleavable PEG linker. So, the 
mechanism of action for this ADC likely involves binding to the cell surface antigen 
(perlecan) on the target cells, followed by slow internalization of the ADC into the 
endo-lysosomes. Lysosomal degradation of the antibody will allow for the release of 
the cytotoxic payload from ADC 108. Because our internalization studies show that 
AM6 is slowly internalized, incorporation of a rapidly cleavable linker in the ADC 
could further improve its anticancer effectiveness.  
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3.5 Conclusion  
Glycoengineered antibody was used to generate AM6-MMAE ADC with a DAR 
of 2-3 drug molecules per antibody. This ADC showed enhanced antitumor efficacy 
in vitro as well as in vivo. Cellular internalization studies suggest that incorporation 
of a cleavable linker in the ADC could further improve its anticancer effectiveness.  
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Chapter 4: Glycoengineered antibodies 
for surface functionalization of 
polymeric nanoparticles   
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4.1 Introduction  
  
Nanoparticles (NPs) have been studied extensively as a drug delivery platform to 
overcome inherent limitations of conventional drugs including unfavorable 
pharmacokinetics, poor solubility and lack of target selectivity 110. Numerous NP 
platforms including drug encapsulating polymeric NPs, self-assembling micellar NPs, 
and drug-polymer conjugates were developed to treat multiple diseases 111. 
Application of NPs to treat cancer have so far shown promising preclinical activity but 
limited clinical success 22.   
Discovery of the enhanced permeability and retention (EPR) effect 112, which 
explains enhanced accumulation of macromolecules via extravasation through leaky 
blood vessels in the tumor, led to an explosive increase in studies examining 
nanoparticles as a carrier for chemotherapy against solid tumors. Two notable 
examples of FDA approved nanomedicines are liposomal doxorubicin (Doxil) and 
albumin bound paclitaxel (Abraxane) 113,114. To further improve NP accumulation and 
retention within tumors, a number of studies have focused on active targeting 
strategies that involve surface modification of the delivery system with a ligand 
capable of binding to components of a tumor. 3,115. Currently used approaches to 
introduce targeting ligands on NPs rely primarily on conjugation via either side-chain 
amine or carboxylic acid groups or conjugation to thiols 92. Because these reactions 
are not site-specific and not easily controlled, these chemistries can result in reduced 
affinity of the ligand for the target antigen.   
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In this chapter, we present the results of our studies examining the use of 
glycoengineering strategy to introduce tumor-targeting antibodies on the surface of 
polymeric nanoparticles. We utilized nanoparticles formulated from the biodegradable 
polymer, poly(D,L-lactide-co-glycolide) (PLGA), as they enable greater and sustained 
cellular delivery of encapsulated payload 116,117. We formulated PLGA NPs that were 
surface functionalized with DBCO-terminated PEG chains and conjugated them to 
glycoengineered anti-perlecan antibody (AM6) using click chemistry. These perlecan 
targeted nanoparticles showed promising efficacy in in vivo models of triple negative 
breast cancer and non-muscle invasive bladder cancer.  
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4.2 Preparation and characterization of antibody 
conjugated nanoparticles   
4.2.1 Method  
4.2.1.1 Materials  
PLGA (50:50, 0.55-0.75Dl/g) was purchased from LACTEL Absorbable Polymers  
(Birmingham, AL). The diblock copolymer polylactide-polyethylene glycol with 
terminal DBCO functionalization (PLA-PEG-DBCO) and rhodamine labeled PLGA 
(PLGA- 
rhodamine) were purchased from PolySciTech (West Lafayette, IN). Polyvinyl 
alcohol (PVA, 30,000-70,000 MW), sucrose and ethylenediaminetetraacetic acid 
(EDTA) were purchased from Sigma (St. Louis, MO). Paclitaxel was purchased from 
Phytogen Life Science (B.C,  
Canada). Control isotype IgG (Cat. No. 401114) was purchased from Calbiochem 
(Billerica, MA). The materials for SDS/PAGE were obtained from Bio-Rad (Hercules, 
CA). HPLC grade organic solvents were obtained from Fisher Scientific (Pittsburgh, 
PA). Cell culture media and buffers (including phosphate buffered saline, PBS) were 
purchased from Corning  
(Tewksbury MA) or Life Technologies (Carlsbad, CA) unless otherwise specified. 
Deionized (DI) water was available through university resources.  
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4.2.1.2 Cell Culture  
MDA-MB-231-LM2 cells were from Joan Massague Laboraotry and have been 
previously described as being derived from lung metastasis arising from parental 
MDA-MB231 tumors in mice. Cells between passages of 2 and 10 were used for all 
the studies. Cells were cultured in minimum essential medium (MEM) with 10% v/v 
fetal bovine serum (FBS) and 1% v/v penicillin/streptomycin in a humidified 
atmosphere with 5% CO2.   
4.2.1.3 Preparation of DBCO Functionalized PLGA Nanoparticles  
PLGA nanoparticles surface functionalized with DBCO-terminated PEG and 
loaded with PTX were synthesized as described in an earlier publication 118, with 
minor modifications. PLGA (30 mg) and PTX (5mg) were dissolved in 1 ml of 
chloroform. An oil-in-water emulsion was formed by emulsifying the polymer-drug 
solution in 8 ml of 2.5% w/v aqueous PVA solution by probe sonication (18–24 W; 
Sonicator XL, Misonix, Melville, NY) for 5 minutes over an ice bath. PLA-PEG-
DBCO (8 mg) was dissolved in chloroform (200 μl) and added dropwise to the above 
emulsion while the emulsion was stirred on a magnetic stirrer. The emulsion was 
stirred further for 16 -18 hours under ambient conditions followed by 1 hour under 
vacuum to remove the residual chloroform. Nanoparticles were washed twice by 
ultracentrifugation (35,000 rpm for 35 min at 4°C, Optima XPN-80, Beckman Palo 
Alta, CA) followed by reconstitution in DI water. The final nanoparticle dispersion 
was then stored at 4°C until it was used for conjugation reaction performed on the 
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same day. Rhodamine labeled nanoparticles were prepared similarly, except PLGA 
(25 mg) and PLGA-rhodamine (5 mg) were used instead of just PLGA.  
4.2.1.4 Preparation and purification of glycoengineered anti-
perlecan antibodies  
Expi293F Expression System by Life Technologies (Carlsbad, CA) was used for 
the expression of anti-perlecan antibodies. During the process of production of 
antibody, 25 μM of Ac4GalNAz sugar was added to the cells with the enhancers a day 
after transfection and also for subsequent three days. Control antibody was made 
without the addition of Ac4GalNAz sugar. Seven days after transfection, affinity 
purification of antibodies was carried out using Protein A Plus (Pierce, Rockford, IL) 
followed by buffer exchange into trisbuffered saline containing 5mM EDTA. ZebaTM 
Spin Desalting Columns (87769, Pierce Biotechnology, Rockford, IL) were used for 
the buffer exchange step. Antibody stocks were stored at -20°C in single use aliquots 
until use. Once thawed, the samples were placed at 4°C for short-term storage. Quality 
control evaluation involved resolution via SDS/PAGE for reduced and non-reduced 
samples and flow cytometry for confirmation of binding affinity.  
4.2.1.5 Conjugation of Antibody to Nanoparticles  
AM6-Az Ab was buffer exchanged into PBS containing 5 mM EDTA (ZebaTM Spin 
Desalting Columns 87769). The desalted antibodies were immediately added to the 
nanoparticle dispersion and placed on a rotating platform at 4°C to allow the 
conjugation reaction to take place overnight. Next morning, nanoparticles were 
washed once by ultracentrifugation (35,000 rpm for 35 min at 4°C) and dispersed in 5 
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ml DI water containing 30 mg sucrose (lyoprotectant – reference Lin’s paper). The 
final dispersion was probe sonicated (30 seconds, 6-9W) on an ice bath and centrifuged 
at 1000 RPM for 5 min to pellet any large aggregates. The supernatant was then 
lyophilized (Labconco, FreeZone 4.5, Kansas City, MO). The lyophilized product was 
stored in a desiccator at 4°C until further use.  
4.2.1.6 Physiochemical Characterization of Nanoparticles  
Hydrodynamic diameter and zeta potential of nanoparticles in DI water were 
determined using DelsaTM Nano C (Beckman Coulter Inc., Fullerton, CA, USA). To 
determine PTX loading, nanoparticles were dispersed in methanol (1 mg/ml) and 
incubated overnight at room temperature. The dispersion was then centrifuged at 
13,000 RPM for 10 min and the supernatant was processed for HPLC analysis. 
Paclitaxel loading was determined using an HPLC method previously described 116. 
HPLC was performed on a Beckman Coulter HPLC system equipped with a System 
Gold 508 autosampler was used. A Beckman Coulter C18 column (4.6 mm x 150 mm, 
5 μm) was used as the stationary phase. The mobile phase consisted of a mixture of 
ammonium acetate (10 mM, pH 4.0) and acetonitrile in 45:55 ratio, and was delivered 
at a flow rate of 1 ml/min. A 50 μl volume of the methanol extract was injected using 
an autoinjector (Model 508, Beckmann Instruments). Paclitaxel was quantified by UV 
detection at 228 nm (System Gold 168 detector).  
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4.2.1.7 Confirmation of Antibody Conjugation and Loading  
One milligram of nanoparticles was dispersed in 40 μl DI water and analyzed for 
protein concentration using bicinchoninic acid assay (Pierce BCA Protein Assay, 
Rockford, IL). In order to confirm chemical conjugation of the antibody to 
nanoparticles we used a gel electrophoresis technique (Swaminathan et al. 2013). One 
milligram of nanoparticles was suspended in 25 μl DI water. To each tube, 25 μl of 
95:5 2X Gel Loading Buffer:2Mercaptoethanol (reduced samples) or 25μl of 2X Gel 
Loading Buffer (non-reduced samples) was added. The samples were placed in a water 
bath at 90°C for 10 min, centrifuged at 13,000 RPM for 10 min and the supernatants 
were resolved on a 4-10% SDS/PAGE Criterion Precast Gel (Bio-Rad, Hercules, CA), 
along with the respective antibody controls.    
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4.2.2 Results  
4.2.2.1  Physiochemical  characterization  of  antibody 
 conjugated nanoparticles  
Average hydrodynamic size of nanoparticles was ~350 nm as measured using DLS. 
Zeta potential was in the range of -12 mV. Presence of antibody did not influence the 
particle size or zeta potential to a significant extent. Paclitaxel encapsulation efficiency 
was greater than 90% and loading was 150 μg/mg of nanoparticles. Antibody 
concentration was between 5-10 μg/mg of nanoparticles, which translates into 
approximately 15-20 antibody molecules/nanoparticle (Table 1).  
Table 1: Physicochemical characterization of nanoparticles  
Characteristics  Anti-perlecan-Az 
NP  
Blank NP  
Nanoparticle Size  364.2 ± 24.8 nm  337 ± 38.3 nm  
Zeta Potential  -12.7 ± 2.7mV  -11.9 ± 3.6mV  
Protein Loading  7 ± 3 μg 
protein/mg NPs   
    -  
Protein  Encapsulation  
Efficiency  
75 ± 25 %     -  
Paclitaxel Loading  15.5% ± 1.7  15.1% ± 2.5  
  
Antibody conjugation to nanoparticles was determined to be between  7 ± 3 μg 
protein/mg nanoparticles. BCA is able to provide information only about the presence 
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or absence of protein. In order to confirm covalent conjugation of the antibody to 
nanoparticles, we analyzed the nanoparticles using SDS/PAGE. 2-mercaptoethanol 
was used to reduce the thiol bonds between the heavy and light chains of the antibody. 
Nanoparticles were incubated under reducing conditions and the reduced samples 
were analyzed using SDS/PAGE. The azide alkyne bond is resistant to reduction by 
2-mercaptoethanol. Thus, when antibody conjugated nanoparticles are subjected to a 
reduction step, only half the antibody molecule is expected to be released from the 
surface of nanoparticles (either the light chain or the heavy chain, depending on which 
is attached to the particle surface). If no reduction step is present, the antibody should 
not be released at all. We were able to confirm this with anti-perlecan-Az antibody 
conjugated nanoparticles (Figure 4.1). Lane 3 represents antibody-conjugated 
nanoparticles that were reduced, and thus we see bands at 25 kDa corresponding to the 
antibody light chains. Lane 4 represents non-reduced antibody-conjugated 
nanoparticles – no bands were observed in this case.  
  
Figure 4.1: SDS/PAGE image showing the presence of antibody in anti-perlecan-Az 
NP   
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4.3 Perlecan-targeted nanoparticles for improved efficacy 
against triple negative breast cancer  
4.3.1 Method  
4.3.1.1 Materials  
The materials for SDS/PAGE were obtained from Bio-Rad (Hercules, CA). HPLC 
grade organic solvents were obtained from Fisher Scientific (Pittsburgh, PA). All cell 
culture media and buffers (including phosphate buffered saline or PBS) were 
purchased from Corning (Tewksbury MA) or Life Technologies (Carlsbad, CA) unless 
otherwise specified. Deionized (DI) water was available through university resources.  
4.3.1.2 Cell culture  
MDA-MB-231-LM2 cells were from Joan Massague laboraotry and have been 
previously described as being derived from lung metastasis arising from parental 
MDA-MB231 tumors in mice. Cells between passages of 2 and 10 were used for all 
the studies. Cells were cultured in minimum essential medium (MEM) with 10% v/v 
fetal bovine serum (FBS) and 1% v/v penicillin/streptomycin in a humidified 
atmosphere with 5% CO2.   
4.3.1.3 Cell uptake of antibody conjugated nanoparticles  
PTX loaded nanoparticles were used for this study. MDA-MB-231-LM2 cells were 
seeded at 50,000 cells per well in a 24-well plate and allowed to adhere overnight. 
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Cells were washed once with PBS and fresh media was added. The cells were 
incubated at 4°C for 2 hours with  
PTX loaded nanoparticles at a final concentration of 100 μg/ml to allow binding to the 
target (n=4). At the end of 2 hours, the media was replaced with fresh media and the 
cells were placed at 37°C to allow internalization. The cells were lysed at 60 minutes 
post addition of treatments using 100 μL RIPA buffer. Part of the cell lysate (30 μL) 
was used to determine protein concentration by BCA assay and the rest was processed 
for HPLC analysis. PTX was extracted into 0.5 mL methanol overnight. The samples 
were centrifuged at 13,000 RPM for 10 min and the supernatant was analyzed for PTX 
concentrations using HPLC 116.  
4.3.1.4 Cytotoxicity study  
MDA-MB-231-LM2 cells were seeded at 2500 cells per well in a 96-well plate and 
allowed to adhere overnight. Treatments (free paclitaxel or paclitaxel loaded 
nanoparticles) were added the next day at concentrations equivalent to 50 nM 
paclitaxel. The treatments were incubated for 6 hours, followed by removal of the 
treatments and addition of fresh media. Cell survival was analyzed at 72 hours using 
CellTiter 96 AQueous One Solution Cell Proliferation Assay (Promega, Madison, 
WI).  
4.3.1.5 Tumor growth inhibition study  
MDA-MB-231-LM2 tumors were grafted in Balb/c homozygous nude mice 
(Jackson Labs). Once tumor volumes reached 100 mm3, three doses of treatments 
equivalent to 40 mg/kg of PTX were administered through tail vein injection once 
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every 96 hrs. Free drug, nanoparticles without the targeting ligand (PEG NP) and 
saline were used as controls (n=7). Tumor volumes were measured every third day 
with digital Vernier calipers (Marathon Watch, Vaughn, Canada). Tumor volumes 
were calculated from the ellipsoid sphere equation V = (L2 * W)/2, L being the longer 
measurement. Two-way ANOVA, with multiple comparison post-hoc tests, was used 
to determine the statistical significance of the data.  
4.3.2 Results  
4.3.2.1 Cell Uptake of Antibody Conjugated Nanoparticles  
Uptake of antibody-conjugated nanoparticles was studied in MDA-MB-231-LM2 
cells, which have been previously established in our laboratory as a perlecan positive 
cell line 120. Presence of the antibody improved internalization of nanoparticles into 
cells as observed by cell uptake data (Figure 4.2). We saw a 2- and 3.5-fold 
improvement in uptake of targeted NP compared to control isotype IgG-conjugated 
NP (P<0.05) and control PEG NP (P<0.05),  
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 Figure 4.2: NP In vitro NP uptake with MDA-MB-231-LM2 cells. Cells incubated with 
antiperlecan-Az NP showed higher uptake (*P<0.05, two way ANOVA with multiple 
comparison tests, statistical significance is based off comparison between PEG NP and 
IgG NP)   
  
4.3.2.2 In vitro cytotoxicity with antibody conjugated nanoparticles  
In order to test the potency of targeted nanoparticles, we performed an in vitro 
cytotoxicity assay with MDA-MB-231-LM2 cells. Treatment with targeted nanoparticles 
resulted in a significantly greater tumor cell kill as compared to the equivalent 
concentration of non-targeted PEG NP and free drug (38% viability as opposed to 64% 
and  53% for PEG NP and PTX,  
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Figure 4.3: : In vitro cytotoxicity study with MDA-MB-231-LM2 cells. Anti-perlecan-
Az NP treated groups showed higher cytotoxicity (*P<0.05, two way ANOVA with 
multiple comparison tests, statistical significance is based off comparison between control 
cells, PTX and PEG NP)   
4.3.2.3 Antibody conjugated nanoparticles result in improved 
efficacy  
  In order to determine the ability of antibody conjugated nanoparticles to improve 
tumortargeted drug delivery in vivo, we tested the efficacy of targeted nanoparticles in the 
MDA-MB231-LM2 orthotopic mouse tumor model (Figure 4.4). Nanoparticles are known 
to have improved accumulation in the tumor due to the enhanced permeability and 
retention (EPR) effect 121. Because of their ability to bind with and get internalized into 
tumor cells, targeted nanoparticles have greater retention in tumors in addition to the EPR 
effect 79,80. We observed improved tumor growth inhibition with perlecan-targeted 
respectively   ) P<0.05, Figure  ( 4 . 3 .  )  
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nanoparticles relative to that with free drug and nontargeted PEG NP (P<0.001, statistical 
significance based on comparison between untreated, free drug and PEG NP on the last 
day of the study). On day 28, the saline, PTX and PEG NP treated animals reached an 
average tumor volume of ~1950 mm3. Only targeted nanoparticles demonstrated tumor 
inhibition at the end of the study.  
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Figure 4.4: Efficacy study in Balb/c athymic nude mice. 40 mg/kg anti-perlecan-Az NP 
showed significantly enhanced tumor inhibition over PTX and PEG NP (**P<0.001, two-
way ANOVA with multiple comparisons, statistical significance is based on comparison 
between untreated, MMAE and AM6-Az Ab on the last day of the study).   
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4.4 Perlecan-targeted nanoparticles for improved efficacy 
against bladder cancer  
4.4.1 Method  
4.4.1.1 Materials  
HPLC grade organic solvents were obtained from Fisher Scientific (Pittsburgh, 
PA). Cell culture media and buffers (including phosphate buffered saline, PBS) were 
purchased from  
Corning (Tewksbury MA) or Life Technologies (Carlsbad, CA) unless otherwise 
specified.  
Deionized (DI) water was available through university resources.  
4.4.1.2 Cell Culture  
MB49 and MB49-luc (murine bladder cancer) cells were a gift from Thomas Griffith at 
the  
University of Minnesota. Cells were cultured in RPMI 1640 with 10% v/v fetal bovine 
serum (FBS) and 1% v/v penicillin/streptomycin in a humidified atmosphere with 5% 
CO2. Human bladder cancer cell lines, RT4 and T24, were also a gift from Thomas 
Griffith at the University of Minnesota. These cells were cultured in RPMI 1640 with 
10% v/v fetal bovine serum (FBS) and 1% v/v penicillin/streptomycin in a humidified 
atmosphere with 5% CO2.  
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4.4.1.3 Binding of glycoengineered anti-perlecan antibodies to 
bladder cancer cell lines  
Flow cytometry was carried out to confirm that anti-perlecan antibody AM6 binds 
to bladder cancer cells. The antibodies were incubated with MB49, RT4 or T24 cells 
at a concentration of 100 nM for 1 hour at 4°C on a rotating platform (Barnstead 
International, Dubuque, IA). The cells were then washed three times using FACS 
Buffer (PBS containing 0.5% BSA, 2mM EDTA and 0.05% sodium azide). Alexa 647 
goat anti-human secondary antibody (Life Technologies, Carlsbad, CA) was added 
and the cells were incubated at 4°C for one 1 hour on a rotating platform. Finally, the 
cells were washed three times, re-suspended in FACS buffer and placed on ice until 
analysis by flow cytometry (BD LSRFortessa).  
4.4.1.4 Cell Uptake of Antibody Conjugated Nanoparticles analyzed 
by flow cytometry  
Rhodamine labeled nanoparticles were used for this study. MB49 cells suspended 
in  FACS buffer (200,000 cells in 150 μL) were incubated with 50 μg of nanoparticles 
(what is the volume?) on a rotating platform at 37°C for 1 hour (n=2). At the end of 
one hour, the cells were washed twice using FACS Buffer, fixed using 4% v/v 
formaldehyde in FACS Buffer, washed once followed by analysis using flow 
cytometry. Flow cytometry analysis was carried out using BD LSRFortessa H0081. 
Mean fluorescence intensity (MFI) from flow cytometry analysis was normalized to 
rhodamine loading in nanoparticles by using fluorescence of the nanoparticle 
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suspensions measured using the IVIS Spectrum in vivo Imaging System (Caliper 
Lifesciences, Hopkinton, MA).  
4.4.1.5 Cytotoxicity Study  
MB49 cells were seeded at 2500 cells per well in a 96-well plate and allowed to 
adhere overnight. Treatments (free paclitaxel or paclitaxel loaded nanoparticles) were 
added the next day at concentrations equivalent to 50 nM paclitaxel. The treatments 
were incubated for 6 hours, followed by removal of the treatments and addition of 
fresh media. Cell survival was analyzed at 72 hours using CellTiter 96 AQueous One 
Solution Cell Proliferation Assay (Promega, Madison, WI).  
4.4.1.6 Development of orthotopic non-muscle invasive bladder 
cancer model  
Female C57BL/6 mice (Charles River Laboratories, Wilmington, MA, USA), 5 
weeks old, were used for developing orthotopic non-muscle invasive bladder cancer 
model. Urethral catheterization in mice under isoflurane was performed using a sterile 
24 G pediatric venous catheter. Following urethral catheterization bladder walls were 
coated with poly-l-lysine (0.05 mL of 0.1 mg/mL) for 5 mins. Bladder was then 
washed with PBS followed by instillation of 0.5 × 106 cells MB49-luc cells (0.05 mL) 
through the urethral catheter for 55 min. Tumors were visualized by bioluminescence 
imaging using the IVIS Spectrum In Vivo Imaging System (University of Minnesota 
Imaging Centre).  
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4.4.1.7 Tumor growth inhibition study  
MB49-luc non-muscle invasive bladder tumors were grafted in C57/bl6 mice 
(Charles River Labs). Once tumor volumes reached  bioluminescence of 104 
photons/sec, three doses of 40 mg/kg of PTX were administered through either tail 
vein injection (IV) or directly into the bladder via urethral catheter (IT) once every 96 
hrs. Isotype IgG-conjugated non-targeted NP and saline were used as controls (n=6). 
Tumor volumes were monitored by bioluminescence imaging using the IVIS 
Spectrum In Vivo Imaging System (University of Minnesota Imaging Centre). Two-
way ANOVA, with multiple comparison post-hoc tests, was used to determine the 
statistical significance of the data.  
4.4.1.8 Immunohistochemistry (IHC)   
At the end of the tumor growth study, mice were sacrificed. Bladders were excised 
and formalin fixed for 24 hours. The tissues were then transferred to 70% ethanol until 
processed.  
The samples were submitted to the University of Minnesota Comparative Pathology 
Shared Resource for IHC processing. The sections were stained for Caspase 3 and 
Ki67. The IHC slides were submitted to the University of Minnesota Imaging Centre 
for slide scanning. Three snippets of approximately 1700 μm x 800 μm size were 
selected at random in the slide field, at 10X magnification and quantified for positive 
staining using the software ImageJ (NIH).  
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4.4.1.9 Accumulation of PTX in bladder   
Orthotopic non-muscle invasive bladder cancer was established in C57/bl6 mice as 
described previously. One week following cell injection, animals were randomly 
assigned to various treatment groups. Targeted and non-targeted nanoparticles 
formulations (40 mg/kg of PTX) were administered either via the tail vein (IV) or 
directly into the bladder via urethral catheter (IT). Cohorts of mice were sacrificed at 
0.5 h, 1 h, 2 h, 6 h or 24 h after treatment administration. Bladder, liver, kidney and 
spleen were collected and weighed. The organs were homogenized with PBS 
containing 5% BSA and lyophilized. Paclitaxel was extracted from the lyophilized 
organs using methyl tert-butyl ether. The ether was separated from the tissue 
homogenate by centrifugation and evaporated to dryness under nitrogen. The dried 
samples were reconstituted in methanol, centrifuged (14000 RPM, 15 min), and 
transferred to HPLC vials. Paclitaxel concentration was analyzed using LC-MS/MS 
as described before 86.  
LC-MS/MS was performed on an Aquity UPLC (Waters) coupled with Micromass 
Quattro Ultima LC/MS/MS (Waters) was used. A Zorbax Eclipse XDB-C18 (50 x 4.6 
x 1.8 mm) was used as the stationary phase. The mobile phase consisted of a mixture 
of water and methanol in 25:75 ratio with 0.1% formic acid (v/v), and was delivered 
at a flow rate of 0.4 ml/min. A 5 μl volume of the methanol extract was injected and 
autosampler temperature was maintained at 10°C. Mass spectrometric detection of 
PTX and IS (Docetaxel) was carried out in positive ion mode using a triple-quadrupole 
mass spectrometer (Waters), equipped with an electrospray ionization interface 
operating at a capillary voltage of 3 kV and cone voltage of 50 V. The collision energy 
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was set at 33 V for PTX and 30 V for IS. Detection of the ions was performed in 
multiple-reaction monitoring mode, monitoring the transition ion pair m/z 876.22/ 
307.91 for PTX and m/z 830.16/548.97 for the IS. The dwell time per transition was  
0.4 sec for both PTX and IS. Data acquisition and peak integration were achieved by  
 MassLynx software, version 4.1.      
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4.4.2 Results  
4.4.2.1 Anti-perlecan antibody binds to bladder cancer cell lines  
It has been previously established in our lab that bladder cancer has high perlecan 
expression 120. We carried out a flow cytometry experiment to determine the expression of 
perlecan in various bladder cancer cell lines. We found that anti-perlecan-Az antibody binds 
to human bladder cancer cell lines RT4 and T24 (Figure 4.5A) as well as to MB49, a murine 
bladder cancer cell line (Figure 4.5B), indicating that these cell lines express perlecan.  
  
 
Figure 4.5: Binding of anti-perlecan-Az Ab to RT4 cells (A), T24 cells (B) and MB49 cells (C).   
4.4.2.2 Cell uptake of antibody conjugated nanoparticles  
Uptake of antibody-conjugated nanoparticles was studied in MB49 cells. Presence of 
antibody improved internalization of nanoparticles into cells (Figure 4.5). We saw a 2-fold 
Control cells  
Anti - perlecan - Azide   
RT4  T24  
MB4 
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improvement in uptake of anti-perlecan-Az NP compared to control isotype IgG NP (P<0.05) 
and a 3-fold improvement in uptake of anti-perlecan-Az NP compared to control PEG NP  
 
Figure 4.6: In vitro NP uptake with MB49 cells. Cells incubated with anti-perlecan-Az NP 
showed higher uptake (*P<0.05, two way ANOVA with multiple comparison tests, statistical 
significance is based off comparison between control cells, DBCO NP and IgG NP)   
4.4.2.3 In vitro cytotoxicity with antibody conjugated nanoparticles  
In order to test the potency of the antibody conjugated nanoparticles, we performed an in vitro 
cytotoxicity assay with MB49 cells. We observed that treatment with anti-perlecan-Az NP 
resulted in a significantly greater tumor cell kill as compared to the equivalent concentration of 
DBCO NP, IgG NP  (31% viability as opposed to 62% and 51% in case of DBCO NP and IgG  
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Figure 4.7: In vitro cytotoxicity study with MB49 cells. Anti-perlecan-Az NP treated groups 
showed higher cytotoxicity (*P<0.05, two way ANOVA with multiple comparison tests, statistical 
significance is based off comparison between control cells, PTX, DBCO NP and IgG NP)   
4.4.2.4 Tumor growth inhibition with antibody conjugated nanoparticles  
 In order to determine the ability of antibody conjugated nanoparticles to improve drug delivery 
in vivo, we tested the efficacy in the MB49 orthotopic non-muscle invasive mouse bladder tumor 
model (Figure 4.7). Previous studies have shown that intra-tumoral administration of the 
treatments leads to increased accumulation of the chemotherapeutic drug with minimal off target 
effects 122–125. So, we compared our formulations via two routes of administration, tail vein 
injection (IV) and directly into the bladder via urethral catheter (IT). We observed complete tumor 
growth inhibition with AM6-Az NP given via IT route (P<0.001, statistical significance is based 
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we observed improved tumor growth inhibition with AM6-Az NP given via IV route as well 
(P<0.001, untreated and IgG NP via IT and IV on the last day of the study).    
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Figure 4.8: Efficacy study in C57/bl6 mice. 40 mg/kg AM6-Az NP administered via urethral 
catheter directly into the bladder showed complete tumor inhibition over IgG NP given via similar 
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route (**P<0.001, two-way ANOVA with multiple comparisons, statistical significance is based 
on comparison between untreated and IgG NP via IT on the last day of the study). 40 mg/kg 
AM6Az NP administered via tail vein injection showed significantly enhanced tumor inhibition 
over IgG NP given via similar route (**P<0.001, two-way ANOVA with multiple comparisons, 
statistical significance is based on comparison between untreated and IgG NP via IT on the last 
day of the study).   
4.4.2.5 Ex vivo immunohistological analysis of tumors  
In addition to monitoring tumor growth, we examined tumor sections from the efficacy 
study for cell proliferation (Ki‐67) and apoptosis (cleaved caspase 3) (Figure 4.8). The 
frequency of Ki‐67 positive cells was significantly (p < 0.05) higher in tumor sections from 
control group, IgG NP (IT) and IgG NP (IV) than that in AM6 NP (IT) and AM6 NP (IV) 
groups. Lowest cell proliferation was observed in sections from tumors treated with AM6 NP 
administered via urethral catheter. Further, there was an increase in the number of apoptotic 
cells in AM6 NP treated tumors (administered via urethral catheter and tail vein injection)  
than that in control and IgG NP treatment groups.   
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Figure 4.9 Ex vivo IHC analysis of bladder cancer tumor collected from efficacy study. (A) 
Representative images presented from each group. (B) Quantified data for percentage Ki67 
positive cells. (C) Quantified data for percentage caspase 3 positive cells. *P<0.05, ordinary 
one-way ANOVA with multiple comparisons compared to control, IgG NP (IT) and IgG NP 
(IV).  
4.4.2.6 Higher PTX accumulation in bladder with urethral catheterization 
route  
We determined the bladder tumor accumulation of AM6 NP and IgG NP, each formulation 
containing PTX (Figure 4.9). The treatments were administered either via intravenous (IV) or 
directly into the bladder via urethral catheter (IT). Treatment with AM6 NP formulations 
administered via IT route led to higher bladder concentration than IgG NP given via the same 
route. In the mice where IgG NP administered via IT route, the PTX concentration in bladder 
decreased with time.  Treatment with AM6 NP formulations administered via IV route led to 








Control IgG NP 
) ( IT 
IgG NP 
( IV ) 
AM6 NP 
( IT ) 
AM6 NP 





















Control IgG NP 
( IT ) 
IgG NP 
( IV ) 
AM6 NP 
( IT ) 
AM6 NP 














  *          *  
*          *  
  91  
 
4.5 Discussion  
  
Conjugation of nanoparticles with antibodies combines the properties of nanoparticles with 
the specific and selective recognition ability of antibodies to antigens 3. Also, the 
improvements in cellular delivery as well as intracellular stability are two additional 
advantages of using antibody conjugated nanoparticles 126.  
   
PLGA was chosen as the polymer of choice due to one primary reason – the degradation 
products i.e. lactic acid and glycolic acid are naturally found in the body and thus toxicity 
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from the excipients would be minimal 127. A number of other groups have used PLGA 
nanoparticles for cancer nanotherapy with minimal toxicity issues 82,128. The nanoparticles 
were grafted on the surface with the block co-polymer PLA-PEG-DBCO using IAASF 
technique 86. The DBCO group served as the reactive functional group on the nanoparticle 
surface for the conjugation of glycoengineered antibody by click chemistry. Characterization 
of the antibody-nanoparticle conjugates revealed a stable bond between the antibody and 
nanoparticles. The physical characteristics of nanoparticles were not significantly affected by 
presence of the antibody, likely due to the small number of antibody molecules conjugated to 
nanoparticles.  
  
Breast cancer takes the lead in the National Cancer Institute’s (NCI) database on funding 
for different types of cancer from 2007 through 2013 129. Close to $600,000,000 has been 
spent on breast cancer research each year 130. This has resulted in improved diagnosis and 
advanced therapeutics, which, in turn, have significantly improved the survival rates of breast 
cancer. However, TNBC patients still have only a few treatment options available to them. In 
addition, most patients develop resistance to these therapies.   
  
Bladder cancer is the second most common cancer of the urogenital tract with nearly 
81,000 new cases and 20,000 deaths expected in 2018 131 . High rates of recurrence require 
lifelong follow-up, which makes bladder cancer one of the costliest cancers to treat. Bladder 
cancer that has invaded the muscle layer may metastasize to liver, lung or bone via the 
lymphatic system. Multimodal therapy of advanced tumors results in only 20-40% survival 
after 5 years 131. Therefore, effective treatment strategies aimed at reducing the recurrence and 
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progression of superficial bladder cancer as well as improving therapeutic outcome in patients 
with advanced disease are urgently needed.  
  
Using phage display, our laboratory has successfully developed anti-perlecan antibody 
(AM6) 120. It has also been shown that, high perlecan expression correlates with significantly 
poorer survival in TNBC and bladder cancer120. So, anti-perlecan antibody conjugated 
nanoparticles were used for targeting TNBC and bladder cancer. We observed a 2-3 fold 
improvement in cell uptake with AM6 NPs in both TNBC and bladder cancer cell lines. There 
was a significant improvement in the in vitro cytotoxicity of paclitaxel when delivered using 
AM6 NPs in both TNBC and bladder cancer cell lines, that can likely be attributed to both 
increased cellular uptake and longer retention of targeted NPs, resulting in higher drug 
concentrations inside the cell.   
  
In vivo studies in a subcutaneous model of TNBC showed significantly improved tumor 
growth inhibition in vivo with AM6 NPs relative to nontargeted isotype IgG NPs. Our 
observation of targeted NPs showing improved therapeutic efficacy is similar to previous 
reports 118,129,132. However, in the non-muscle invasive bladder cancer model, we observed 
complete tumor growth inhibition with AM6-Az NP given through the urethral catheter and 
improved tumor growth inhibition with AM6-Az NP given via tail vein relative to nontargeted 
isotype IgG NPs given via both the routes. This data correlates with the higher PTX 
concentrations observed in bladder with AM6-Az NP given through the urethral catheter. Also, 
the PTX bladder concentration in mice administered with IgG NP via urethral catheter also 
decreased over time indicating that nanoparticles conjugated to nonspecific antibody may not be 
binding to the tumor cells on the bladder wall. Increase in the PTX concentration with AM6-Az 
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NP is likely due to the binding of the anti-perlecan antibody to perlecan expressed on the tumor 
cells. These results thus indicate that administering NPs directly into the bladder improves 
antitumor efficacy, which is similar to the previous reports that show improved tumor growth 
inhibition following local delivery of nanomedicine 77,122,123,133. It is interesting to note that 
the IV delivery results in significant tumor growth inhibition (albeit less than that following 
the intravesical route). This may be because of effective targeting of NPs to the bladder tumor 
following IV delivery. It will be interesting to determine differences in toxicity and side 
effects (arising from non-specific distribution of PTX) between the IV and IT route.  
    
4.6 Conclusion  
Glycoengineered AM6 antibody was used to generate perlecan-targeted nanoparticles loaded 
with paclitaxel. These antibody conjugated nanoparticles showed enhanced antitumor efficacy 
in vitro as well as in vivo in TNBC models. Targeted nanoparticles also demonstrated 
enhanced antitumor efficacy in vitro and complete tumor growth inhibition in vivo in a non- 
 muscle invasive bladder cancer model.     
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 Chapter 5: Summary     
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The central objective of this thesis was to advance a new antibody glycoengineering 
technology that will allow for facile synthesis of antibody-based drug delivery systems. In 
order to accomplish this objective, we expressed antibodies with artificial azide groups using 
a novel glycoengineering strategy. This strategy involved incorporation of azido sugars in the 
N-glycan region of anti-perlecan and anti-CD133 antibodies. The results indicated that 
glycoengineering strategy can be used for different production systems and for different 
antibodies. Further, cyclooctyne containing payloads including fluorophores and PEG 
conjugates were successfully conjugated to glycoengineered antibodies using click chemistry. 
Upon quantification we found that we were able to incorporate 2-3 azide molecules per 
antibody. Our studies showed that incorporation of azido sugars and subsequent click reaction 
did not affect the antigen binding or in vivo tumor accumulation of the antibody. In future, 
the number of azide groups introduced per antibody can be further increased by completely 
depleting the natural sugars in the media during the production of the antibody and substituting 
it with non-natural sugars containing azide.   
Antibodies in the clinic have been utilized for versatile applications including, but not 
limited to, antibody-drug conjugates, diagnostic agents, targeting ligands and as therapeutics 
themselves. In chapters 3 and 4, we developed two different types of antibody conjugates viz., 
antibody drug conjugate (ADC) and antibody conjugated nanoparticles for therapeutic 
applications using the glycoengineered antibody.  
In chapter 3, our strategy for site-specific antibody drug conjugation technology involved 
coupling drug molecules to modified N-glycans on the antibody. The ADC with 
glycoengineered anti-perlecan antibody, DBCO-PEG as the linker and monomethyl auristatin  
  97  
E as the drug had 2-3 drug molecules per antibody. This ADC enhanced antitumor efficacy in 
vitro as well as in vivo. We also performed internalization studies with anti-perlecan antibody, 
which suggested that it is slowly internalized into tumor cells. This suggests that using 
cleavable linker technology in the ADC could further improve its anticancer effectiveness in 
future.  
In chapter 4, glycoengineered anti-perlecan antibody was used to generate antibody 
conjugated nanoparticles. PTX loaded PLGA nanoparticles were surface functionalized with 
PLA-PEG DBCO using a previously developed technique in lab. The DBCO group served as 
the reactive functional group on the nanoparticle surface for conjugation of glycoengineered 
antibody via click chemistry. We were able to achieve a stable bond between the antibody and 
nanoparticles without affecting the physical characteristics of nanoparticles or the antigen 
affinity of antibody. These antibody conjugated nanoparticles showed enhanced antitumor 
efficacy in vitro as well as in vivo in TNBC models. These targeted nanoparticles also 
demonstrated enhanced antitumor efficacy in vitro and complete tumor growth inhibition in 
vivo in a non-muscle invasive bladder cancer model.  
In conclusion, our studies show that the antibody glycoengineering strategy advanced here 
is an effective approach for incorporating drug payload in the antibody, and can therefore be 
expected have a significant impact on antibody-based therapeutics.  
  
    
  
  98  
Bibliography  
  
1. Adams GP, Weiner LM. Monoclonal antibody therapy of cancer. Nat Biotechnol.  
2005;23(9):1147-1157. doi:10.1038/nbt1137  
2. Smolen JS, Aletaha D. Rheumatoid arthritis therapy reappraisal: Strategies, 
opportunities and challenges. Nat Rev Rheumatol. 2015;11(5):276-289. 
doi:10.1038/nrrheum.2015.8  
3. Arruebo M, Valladares M, González-Fernández Á. Antibody-conjugated 
nanoparticles for biomedical applications. J Nanomater. 2009;2009. 
doi:10.1155/2009/439389  
4. Flemming A. Fine-tuning antibody–drug conjugates. Nat Rev Drug Discov.  
2014;13(3):178. doi:10.1038/nrd4266  
5. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity’s 
roles in cancer suppression and promotion. Science. 2011;331(6024):1565-1570. 
doi:10.1126/science.1203486  
6. Farkona S, Diamandis EP, Blasutig IM. Cancer immunotherapy: The beginning of 
the end of cancer? BMC Med. 2016;14(1):1-18. doi:10.1186/s12916-016-0623-5  
7. Jefferis R. CCE IX : Review Glycosylation of Recombinant Antibody 
Therapeutics.  
Society. 2005:11-16.  
8. Ecker DM, Jones SD, Levine HL. The therapeutic monoclonal antibody market. 
MAbs.  
2015;7(1):9-14. doi:10.4161/19420862.2015.989042  
9. Lobo ED, Hansen RJ, Balthasar JP. Antibody pharmacokinetics and 
pharmacodynamics. J  
Pharm Sci. 2004;93(11):2645-2668. doi:10.1002/jps.20178  
10. Lucas A, Price L, Schorzman A, et al. Factors Affecting the Pharmacology of 
Antibody– 
Drug Conjugates. Antibodies. 2018;7(1):10. doi:10.3390/antib7010010  
11. Otagiri M, Giam Chuang VT, Immunobiology, Murphy K, Weaver C. Janeway ’ S 
9 Th  
Edition.; 2017. doi:10.1007/978-981-10-2116-9  
  99  
12. Rayner LE, Hui GK, Gor J, Heenan RK, Dalby PA, Perkins SJ. The solution 
structures of two human IgG1 antibodies show conformational stability and accommodate 
their C1q and FcγR ligands. J Biol Chem. 2015;290(13):8420-8438. 
doi:10.1074/jbc.M114.631002  
13. Lambert JM, Morris CQ. Antibody–Drug Conjugates (ADCs) for Personalized 
Treatment of Solid Tumors: A Review. Adv Ther. 2017;34(5):1015-1035. 
doi:10.1007/s12325-017- 
0519-6  
14. Uzman A. Molecular biology of the cell (4th ed.): Alberts, B., Johnson, A., Lewis, 
J.,  
Raff, M., Roberts, K., and Walter, P. Biochem Mol Biol Educ. 2003;31(4):212-214. 
doi:doi:10.1002/bmb.2003.494031049999  
15. Milstein C, Alerts E. Pillars Article : Continuous cultures of fused cells secreting 
antibody of predefined. Nature. 1975;256(5517):495-497.  
16. Issa F. Remote control of therapeutic T cells through a small molecule-gated 
chimeric receptor. Transplantation. 2015;99(12):2434. 
doi:10.1097/TP.0000000000001016  
17. Pirofski L, Casadevall A, Rodriguez L, Zuckier LS, Scharff MD. Current state of 
the hybridoma technology. J Clin Immunol. 1990;10(6 Supplement). 
doi:10.1007/BF00918686  
18. Brekke OH, Sandlie I. Therapeutic antibodies for human diseases at the dawn of 
the twenty-first century. Nat Rev Drug Discov. 2003;2(1):52-62. doi:10.1038/nrd984  
19. Smith SL. Ten Years of Orthoclone OKT3 (Muromonab-CD3): A Review. J 
Transpl  
Coord. 1996;6(3):109-121. doi:10.1177/090591999600600304  
20. Harding FA, Stickler MM, Razo J, DuBridge RB. The immunogenicity of 
humanized and fully human antibodies: Residual immunogenicity resides in the CDR 
regions. MAbs.  
2010;2(3):256-265. doi:10.4161/mabs.2.3.11641  
21. Wang Q, Chung CY, Chough S, Betenbaugh MJ. Antibody glycoengineering 
strategies in mammalian cells. Biotechnol Bioeng. 2018;115(6):1378-1393. 
doi:10.1002/bit.26567  
22. Cho K, Wang X, Nie S, Chen Z, Shin DM. Therapeutic nanoparticles for drug 
delivery in cancer. Clin Cancer Res. 2008;14(5):1310-1316. doi:10.1158/1078-0432.CCR-
07-1441  
23. Tonelli AR, Lottenberg R, Allan RW, Sriram PS. Rituximab-induced 
hypersensitivity pneumonitis. Respiration. 2009;78(2):225-229. doi:10.1159/000163069  
24. The official website of the Nobel Prize - NobelPrize.org. 
https://www.nobelprize.org/.  
  100  
Accessed December 4, 2019.  
25. Humira | AbbVie. https://www.abbvie.com/our-science/pipeline/humira.html. 
Accessed  
December 4, 2019.  
26. Nixon AE, Sexton DJ, Ladner RC. Drugs derived from phage display from 
candidate identification to clinical practice. MAbs. 2014;6(1):73-85. 
doi:10.4161/mabs.27240  
27. Urquhart L. Top drugs and companies by sales in 2018. Nat Rev Drug Discov. 
March  
2019. doi:10.1038/d41573-019-00049-0  
28. Bazan J, Całkosiñski I, Gamian A. Phage displaya powerful technique for 
immunotherapy: 1. Introduction and potential of therapeutic applications. Hum Vaccines  
Immunother. 2012;8(12):1817-1828. doi:10.4161/hv.21703  
29. Wang L, Amphlett G, Blättler WA, Lambert JM, Zhang W. Structural 
characterization of the maytansinoid-monoclonal antibody immunoconjugate, huN901-
DM1, by mass spectrometry. Protein Sci. 2005;14(9):2436-2446. 
doi:10.1110/ps.051478705  
30. Strohl WR. Current progress in innovative engineered antibodies. Protein Cell. 
2018;9(1):86-120. doi:10.1007/s13238-017-0457-8  
31. Kanyavuz A, Marey-Jarossay A, Lacroix-Desmazes S, Dimitrov JD. Breaking the 
law:  
unconventional strategies for antibody diversification. Nat Rev Immunol. 2019;19(6):355- 
368. doi:10.1038/s41577-019-0126-7  
32. Liu L. Antibody glycosylation and its impact on the pharmacokinetics and 
pharmacodynamics of monoclonal antibodies and Fc-fusion proteins. J Pharm Sci.  
2015;104(6):1866-1884. doi:10.1002/jps.24444  
33. Stefanich EG, Ren S, Danilenko DM, et al. Evidence for an asialoglycoprotein 
receptor on nonparenchymal cells for O-linked glycoproteins. J Pharmacol Exp Ther.  
2008;327(2):308-315. doi:10.1124/jpet.108.142232  
34. Pennica D, Lam VT, Weber RF, et al. Biochemical characterization of the 
extracellular domain of the 75-kilodalton tumor necrosis factor receptor. Biochemistry.  
1993;32(12):3131-3138. doi:10.1021/bi00063a027  
  101  
35. Arnold JN, Wormald MR, Sim RB, Rudd PM, Dwek RA. The Impact of 
Glycosylation on the Biological Function and Structure of Human Immunoglobulins. Annu 
Rev Immunol. 2007;25(1):21-50. doi:10.1146/annurev.immunol.25.022106.141702  
36. Krapp S, Mimura Y, Jefferis R, Huber R, Sondermann P. Structural Analysis of 
Human  
IgG-Fc Glycoforms Reveals a Correlation Between Glycosylation and Structural Integrity.  
J Mol Biol. 2003;325(5):979-989. doi:10.1016/S0022-2836(02)01250-0  
37. Jefferis R. Isotype and glycoform selection for antibody therapeutics. Arch 
Biochem  
Biophys. 2012;526(2):159-166. doi:10.1016/J.ABB.2012.03.021  
38. Hayes JM, Cosgrave EFJ, Struwe WB, et al. Glycosylation and Fc receptors. Curr 
Top  
Microbiol Immunol. 2014;382:165-199. doi:10.1007/978-3-319-07911-0_8  
39. Kornfeld R, Kornfeld S. Assembly of asparagine-linked oligosaccharides. Annu 
Rev  
Biochem. 1985;54:631-664. doi:10.1146/annurev.bi.54.070185.003215  
40. Kornfeld R, Kornfeld S. Comparative aspects of glycoprotein structure. Annu Rev  
Biochem. 1976;45:217-237. doi:10.1146/annurev.bi.45.070176.001245  
41. Kornfeld R, Keller J, Baenziger J, Kornfeld S. The structure of the glycopeptide of 
human gamma G myeloma proteins. J Biol Chem. 1971;246(10):3259-3268.  
42. Kolb HC, Sharpless KB. The growing impact of click chemistry on drug discovery. 
Drug  
Discov Today. 2003;8(24):1128-1137. doi:10.1016/S1359-6446(03)02933-7  
43. Agard NJ, Prescher JA, Bertozzi CR. A Strain-Promoted [3 + 2] Azide−Alkyne 
Cycloaddition for Covalent Modification of Biomolecules in Living Systems. J Am Chem  
Soc. 2004;126(46):15046-15047. doi:10.1021/ja044996f  
44. Tornøe CW, Christensen C, Meldal M. Peptidotriazoles on Solid Phase:  [1,2,3]-
Triazoles by Regiospecific Copper(I)-Catalyzed 1,3-Dipolar Cycloadditions of Terminal 
Alkynes to  
Azides. J Org Chem. 2002;67(9):3057-3064. doi:10.1021/jo011148j  
  102  
45. Rostovtsev V V., Green LG, Fokin V V., Sharpless KB. A Stepwise Huisgen 
Cycloaddition Process: Copper(I)-Catalyzed Regioselective “Ligation” of Azides and 
Terminal Alkynes. Angew Chemie Int Ed. 2002;41(14):2596-2599. doi:10.1002/1521- 
3773(20020715)41:14<2596::AID-ANIE2596>3.0.CO;2-4  
46. Of H, Information P. Reference ID : 3662552 DESCRIPTION Reference ID : 
3662552.  
2011;(2).  
47. See full prescribing information for complete boxed warning •. 2019.  
48. FULL PRESCRIBING INFORMATION WARNING : HEPATOTOXICITY  
Hepatotoxicity , including severe or fatal hepatic veno-occlusive disease ( VOD ), also  
known as sinusoidal obstruction syndrome ( SOS ), has been reported in association with 
the use of MYLOTARG as a . 2000:1-19.  
49. Reference ID : 4140675 Reference ID : 4140675. 2017:1-26.  
50. FULL PRESCRIBING INFORMATION WARNING : CAPILLARY LEAK 
SYNDROME and HEMOLYTIC UREMIC SYNDROME   Capillary Leak Syndrome (  
CLS ), including life-threatening cases , occurred in patients receiving LUMOXITI .  
Monitor weight and blood pressure ; check labs , i. 2018:1-25.  
51. INDICATIONS AND USAGE POLIVY in combination with bendamustine and a  
rituximab product is indicated for the treatment of adult patients with relapsed or 
refractory diffuse large B-cell lymphoma ( DLBCL ), not otherwise specified , after at 
least two prior . 2019.  
52. Ducry L, Stump B. Antibody-drug conjugates: linking cytotoxic payloads to 
monoclonal antibodies. Bioconjug Chem. 2010;21(1):5-13. doi:10.1021/bc9002019  
53. Sievers EL, Senter PD. Antibody-drug conjugates in cancer therapy. Annu Rev 
Med.  
2013;64:15-29. doi:10.1146/annurev-med-050311-201823  
54. Nolting B. Linker technologies for antibody-drug conjugates. Methods Mol Biol.  
2013;1045:71-100. doi:10.1007/978-1-62703-541-5_5  
55. Bareford LM, Swaan PW. Endocytic mechanisms for targeted drug delivery. Adv 
Drug  
Deliv Rev. 2007;59(8):748-758. doi:10.1016/j.addr.2007.06.008  
  103  
56. Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev  
Immunol. 2007;7(9):715-725. doi:10.1038/nri2155  
57. Ritchie M, Tchistiakova L, Scott N. Implications of receptor-mediated endocytosis 
and intracellular trafficking dynamics in the development of antibody drug conjugates. 
MAbs. 2013;5(1):13-21. doi:10.4161/mabs.22854  
58. Chari RVJ. Targeted cancer therapy: conferring specificity to cytotoxic drugs. Acc 
Chem  
Res. 2008;41(1):98-107. doi:10.1021/ar700108g  
59. Teicher BA, Chari RVJ. Antibody conjugate therapeutics: challenges and potential. 
Clin  
Cancer Res. 2011;17(20):6389-6397. doi:10.1158/1078-0432.CCR-11-1417  
60. Chari RVJ, Miller ML, Widdison WC. Antibody-drug conjugates: an emerging 
concept in cancer therapy. Angew Chem Int Ed Engl. 2014;53(15):3796-3827.  
doi:10.1002/anie.201307628  
61. Senter PD, Sievers EL. The discovery and development of brentuximab vedotin for 
use in relapsed Hodgkin  lymphoma and systemic anaplastic large cell lymphoma. Nat  
Biotechnol. 2012;30(7):631-637. doi:10.1038/nbt.2289  
62. Lambert JM, Chari RVJ. Ado-trastuzumab Emtansine (T-DM1): an antibody-drug 
conjugate (ADC) for HER2-positive breast cancer. J Med Chem. 2014;57(16):6949-6964.  
doi:10.1021/jm500766w  
63. Smith AL, Nicolaou KC. The enediyne antibiotics. J Med Chem. 
1996;39(11):2103-2117. doi:10.1021/jm9600398  
64. Pettit GR, Kamano Y, Herald CL, et al. The isolation and structure of a remarkable 
marine animal antineoplastic constituent: dolastatin 10. J Am Chem Soc. 
1987;109(22):6883- 
6885. doi:10.1021/ja00256a070  
65. Widdison WC, Wilhelm SD, Cavanagh EE, et al. Semisynthetic maytansine 
analogues for the targeted treatment of cancer. J Med Chem. 2006;49(14):4392-4408. 
doi:10.1021/jm060319f  
66. Kupchan SM, Sneden AT, Branfman AR, et al. Structural requirements for 
antileukemic activity among the naturally occurring and semisynthetic maytansinoids. J 
Med Chem.  
1978;21(1):31-37. doi:10.1021/jm00199a006  
  104  
67. Singh R, Lambert JM, Chari RVJ. Antibody-Drug Conjugates: New Frontier in 
Cancer  
Therapeutics. Handb Ther Antibodies. September 2014:341-362. 
doi:doi:10.1002/9783527682423.ch13  
68. Singh R, Setiady YY, Ponte J, et al. A New Triglycyl Peptide Linker for Antibody-
Drug  
Conjugates (ADCs) with Improved  Targeted Killing of Cancer Cells. Mol Cancer Ther.  
2016;15(6):1311-1320. doi:10.1158/1535-7163.MCT-16-0021  
69. Erickson HK, Widdison WC, Mayo MF, et al. Tumor delivery and in vivo 
processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates. 
Bioconjug Chem.  
2010;21(1):84-92. doi:10.1021/bc900315y  
70. Erickson HK, Park PU, Widdison WC, et al. Antibody-maytansinoid conjugates 
are activated in targeted cancer cells by lysosomal degradation and linker-dependent 
intracellular processing. Cancer Res. 2006;66(8):4426-4433. doi:10.1158/0008- 
5472.CAN-05-4489  
71. Erickson HK, Lambert JM. ADME of antibody-maytansinoid conjugates. AAPS J.  
2012;14(4):799-805. doi:10.1208/s12248-012-9386-x  
72. Sharkey RM, Goldenberg DM. Use of antibodies and immunoconjugates for the 
therapy of more accessible cancers. Adv Drug Deliv Rev. 2008;60(12):1407-1420. 
doi:10.1016/j.addr.2008.04.011  
73. Desai MP, Labhasetwar V, Walter E, Levy RJ, Amidon GL. The mechanism of 
uptake of biodegradable microparticles in Caco-2 cells is size dependent. Pharm Res.  
1997;14(11):1568-1573. doi:10.1023/a:1012126301290  
74. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as 
an emerging platform for cancer therapy. Nat Nanotechnol. 2007;2(12):751-760.  
doi:10.1038/nnano.2007.387  
75. Hashizume H, Baluk P, Morikawa S, et al. Openings between defective endothelial 
cells explain tumor vessel leakiness. Am J Pathol. 2000;156(4):1363-1380. 
doi:10.1016/S00029440(10)65006-7  
76. Leu AJ, Berk DA, Lymboussaki A, Alitalo K, Jain RK. Absence of functional 
lymphatics within a murine sarcoma: a molecular and functional evaluation. Cancer Res.  
2000;60(16):4324-4327.  
77. Torchilin V. Tumor delivery of macromolecular drugs based on the EPR effect. 
Adv Drug  
  105  
Deliv Rev. 2011;63(3):131-135. doi:10.1016/j.addr.2010.03.011  
78. Does nanomedicine have a delivery problem? | June 20, 2016 Issue - Vol. 94 Issue 
25 | Chemical & Engineering News. https://cen.acs.org/articles/94/i25/Does-
nanomedicinedelivery-problem.html. Accessed December 8, 2019.  
79. Bartlett DW, Su H, Hildebrandt IJ, Weber WA, Davis ME. Impact of tumor-
specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by 
multimodality in vivo imaging. Proc Natl Acad Sci U S A. 2007;104(39):15549-15554. 
doi:10.1073/pnas.0707461104  
80. Kirpotin DB, Drummond DC, Shao Y, et al. Antibody targeting of long-circulating 
lipidic nanoparticles does not increase tumor localization but does increase internalization 
in animal models. Cancer Res. 2006;66(13):6732-6740. doi:10.1158/0008-5472.CAN-05- 
4199  
81. Xu Y, Kim C-S, Saylor DM, Koo D. Polymer degradation and drug delivery in 
PLGAbased drug-polymer applications: A  review of experiments and theories. J Biomed 
Mater  
Res B Appl Biomater. 2017;105(6):1692-1716. doi:10.1002/jbm.b.33648  
82. Panyam J, Labhasetwar V. Biodegradable nanoparticles for drug and gene delivery 
to cells and tissue. Adv Drug Deliv Rev. 2003;55(3):329-347. doi:10.1016/s0169-
409x(02)00228- 
4  
83. Panyam J, Zhou W-Z, Prabha S, Sahoo SK, Labhasetwar V. Rapid endo-lysosomal 
escape of poly(DL-lactide-co-glycolide) nanoparticles: implications for drug and gene 
delivery.  
FASEB J  Off Publ Fed Am Soc  Exp Biol. 2002;16(10):1217-1226. doi:10.1096/fj.02- 
0088com  
84. Owens DE 3rd, Peppas NA. Opsonization, biodistribution, and pharmacokinetics 
of polymeric nanoparticles. Int J Pharm. 2006;307(1):93-102. 
doi:10.1016/j.ijpharm.2005.10.010  
85. Harris JM, Chess RB. Effect of pegylation on pharmaceuticals. Nat Rev Drug 
Discov.  
2003;2(3):214-221. doi:10.1038/nrd1033  
86. Patil YB, Toti US, Khdair A, Ma L, Panyam J. Single-step surface functionalization 
of polymeric nanoparticles for targeted drug delivery. Biomaterials. 2009;30(5):859-866. 
doi:10.1016/J.BIOMATERIALS.2008.09.056  
87. Nejadmoghaddam M, Minai-tehrani A, Ghahremanzadeh R. Antibody-Drug 
Conjugates :  
  106  
Possibilities and Challenges. 2019;11(1).  
88. Dhakal D, Dhakal Y, Sohng JK. Book Review : Antibody-Drug Conjugates :  
Fundamentals , Drug Development , and Clinical Outcomes to Target Cancer.  
2017;8(October):3-5. doi:10.1021/bc5004982  
89. Vidarsson G, Dekkers G, Rispens T. IgG subclasses and allotypes: From structure 
to effector functions. Front Immunol. 2014;5(OCT). doi:10.3389/fimmu.2014.00520  
90. Strop P, Liu SH, Dorywalska M, et al. Location matters: Site of conjugation 
modulates stability and pharmacokinetics of antibody drug conjugates. Chem Biol. 
2013;20(2):161- 
167. doi:10.1016/j.chembiol.2013.01.010  
91. Yamada K, Ito Y. Recent Chemical Approaches for Site‐Specific Conjugation of 
Native  
Antibodies: Technologies toward Next‐Generation Antibody–Drug Conjugates.  
ChemBioChem. 2019:2729-2737. doi:10.1002/cbic.201900178  
92. Van Geel R, Wijdeven MA, Heesbeen R, et al. Chemoenzymatic Conjugation of 
Toxic Payloads to the Globally Conserved N-Glycan of Native mAbs Provides 
Homogeneous and Highly Efficacious Antibody-Drug Conjugates. Bioconjug Chem. 
2015;26(11):22332242. doi:10.1021/acs.bioconjchem.5b00224  
93. O’Connor LJ, Mistry IN, Collins SL, et al. CYP450 Enzymes Effect Oxygen-
Dependent  
Reduction of Azide-Based Fluorogenic Dyes. ACS Cent Sci. 2017;3(1):20-30. 
doi:10.1021/acscentsci.6b00276  
94. Swaminathan SK, Olin MR, Forster CL, Cruz KSS, Panyam J, Ohlfest JR. 
Identification of a novel monoclonal antibody recognizing CD133. J Immunol Methods. 
2010;361(1- 
2):110-115. doi:10.1016/J.JIM.2010.07.007  
95. Toma A, Otsuji E, Kuriu Y, et al. Monoclonal antibody A7-superparamagnetic iron 
oxide as contrast agent of MR imaging of rectal carcinoma. Br J Cancer. 2005;93(1):131-
136. doi:10.1038/sj.bjc.6602668  
96. Takashima H, Tsuji AB, Saga T, et al. Molecular imaging using an anti-human 
tissue factor monoclonal antibody in an orthotopic glioma xenograft model. Sci Rep.  
2017;7(1):4-9. doi:10.1038/s41598-017-12563-5  
97. Ju M-S, Jung ST. Aglycosylated full-length IgG antibodies: steps toward next-
generation immunotherapeutics. Curr Opin Biotechnol. 2014;30:128-139.  
doi:10.1016/J.COPBIO.2014.06.013  
  107  
98. Acchione M, Kwon H, Jochheim CM, Atkins WM. Impact of linker and 
conjugation chemistry on antigen binding, Fc receptor binding and thermal stability of 
model antibody-drug conjugates. MAbs. 2012;4(3):362-372. doi:10.4161/mabs.19449  
99. Ordás I, Mould DR, Feagan BG, Sandborn WJ. Anti-TNF monoclonal antibodies 
in inflammatory bowel disease: Pharmacokinetics-based dosing paradigms. Clin 
Pharmacol Ther. 2012;91(4):635-646. doi:10.1038/clpt.2011.328  
100. Krop IE, Kim S-B, González-Martín A, et al. Trastuzumab emtansine versus 
treatment of physician’s choice for pretreated HER2-positive advanced breast cancer 
(TH3RESA): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15(7):689-699.  
doi:10.1016/S1470-2045(14)70178-0  
101. Hurvitz SA, Dirix L, Kocsis J, et al. Phase II randomized study of trastuzumab 
emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth 
factor receptor 2-positive metastatic breast cancer. J Clin Oncol. 2013;31(9):1157-1163. 
doi:10.1200/JCO.2012.44.9694  
102. Gopal AK, Chen R, Smith SE, et al. Durable remissions in a pivotal phase 2 study 
of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma. Blood.  
2015;125(8):1236-1243. doi:10.1182/blood-2014-08-595801  
103. Lewis Phillips GD, Li G, Dugger DL, et al. Targeting HER2-positive breast cancer 
with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res. 
2008;68(22):9280- 
9290. doi:10.1158/0008-5472.CAN-08-1776  
104. Francisco JA, Cerveny CG, Meyer DL, et al. cAC10-vcMMAE, an anti-
CD30monomethyl auristatin E conjugate with potent and selective antitumor activity. 
Blood.  
2003;102(4):1458-1465. doi:10.1182/blood-2003-01-0039  
105. Lee B-C, Chalouni C, Doll S, et al. FRET Reagent Reveals the Intracellular 
Processing of  
Peptide-Linked Antibody–Drug Conjugates. Bioconjug Chem. 2018;29(7):2468-2477. 
doi:10.1021/acs.bioconjchem.8b00362  
106. Wakankar A, Chen Y, Gokarn Y, Jacobson FS. Analytical methods for 
physicochemical characterization of antibody drug conjugates. MAbs. 2011;3(2):164-175.  
doi:10.4161/mabs.3.2.14960  
107. Hamblett KJ, Senter PD, Chace DF, et al. Effects of drug loading on the antitumor 
activity of a monoclonal antibody drug conjugate. Clin Cancer Res. 2004;10(20):7063-
7070.  
doi:10.1158/1078-0432.CCR-04-0789  
108. Peters C, Brown S. Antibody-drug conjugates as novel anti-cancer 
chemotherapeutics.  
  108  
Biosci Rep. 2015;35(4). doi:10.1042/BSR20150089  
109. Hashida S, Imagawa M, Inoue S, Ruan KH, Ishikawa E. More useful maleimide 
compounds for the conjugation of Fab’ to horseradish peroxidase through thiol groups in 
the hinge. J Appl Biochem. 1984;6(1-2):56-63.  
110. Labhasetwar V, Song C, Levy RJ. Nanoparticle drug delivery system for restenosis. 
Adv  
Drug Deliv Rev. 1997;24(1):63-85. doi:10.1016/S0169-409X(96)00483-8  
111. Gelperina S, Kisich K, Iseman MD, Heifets L. The potential advantages of 
nanoparticle drug delivery systems in chemotherapy of tuberculosis. Am J Respir Crit Care 
Med.  
2005;172(12):1487-1490. doi:10.1164/rccm.200504-613PP  
112. Fang J, Nakamura H, Maeda H. The EPR effect: Unique features of tumor blood 
vessels for drug delivery, factors involved, and limitations and augmentation of the effect. 
Adv  
Drug Deliv Rev. 2011;63(3):136-151. doi:10.1016/j.addr.2010.04.009  
113. Roque MC, Franco MS, Vilela JMC, Andrade MS, Barros ALB de, Oliveira* EAL 
and  
MC. Development of Long-Circulating and Fusogenic Liposomes Coencapsulating 
Paclitaxel and Doxorubicin in Synergistic Ratio for the Treatment of Breast Cancer. Curr  
Drug Deliv. 2019;16(9):829-838.  
doi:http://dx.doi.org/10.2174/1567201816666191016112717  
114. Micha JP, Goldstein BH, Birk CL, Rettenmaier MA, Brown J V. Abraxane in the 
treatment of ovarian cancer: The absence of hypersensitivity reactions. Gynecol Oncol.  
2006;100(2):437-438. doi:10.1016/j.ygyno.2005.09.012  
115. Roux KH, Strelets L, Michaelsen TE. Flexibility of human IgG subclasses. J 
Immunol.  
1997;159(7):3372 LP - 3382. http://www.jimmunol.org/content/159/7/3372.abstract.  
116. Patil Y, Panyam J. Polymeric nanoparticles for siRNA delivery and gene silencing. 
Int J  
Pharm. 2009;367(1-2):195-203. doi:10.1016/j.ijpharm.2008.09.039  
117. Toti US, Guru BR, Hali M, et al. Targeted delivery of antibiotics to intracellular 
chlamydial infections using PLGA nanoparticles. Biomaterials. 2011;32(27):6606-6613.  
doi:10.1016/j.biomaterials.2011.05.038  
  109  
118. Swaminathan SK, Roger E, Toti U, Niu L, Ohlfest JR, Panyam J. CD133-targeted 
paclitaxel delivery inhibits local tumor recurrence in a mouse model of breast cancer. J  
Control Release. 2013;171(3):280-287. doi:10.1016/J.JCONREL.2013.07.014  
119. Patil YB, Swaminathan SK, Sadhukha T, Ma L, Panyam J. The use of 
nanoparticlemediated targeted gene silencing and drug delivery to overcome tumor drug 
resistance. Biomaterials. 2010;31(2):358-365. 
doi:10.1016/J.BIOMATERIALS.2009.09.048  
120. Kalscheuer S, Khanna V, Kim H, et al. Discovery of HSPG2 ( Perlecan ) as a 
Therapeutic  
Target in Triple Negative Breast Cancer. 2019;2(August):1-11. doi:10.1038/s41598-019- 
48993-6  
121. Murakami M, Cabral H, Matsumoto Y, et al. Improving drug potency and efficacy 
by nanocarrier-mediated subcellular targeting. Sci Transl Med. 2011;3(64).  
doi:10.1126/scitranslmed.3001385  
122. Shen L, Zhang Z, Wang T, Yang X, Huang R, Quan D. Reversed lipid-based 
nanoparticles dispersed in oil for malignant tumor treatment via intratumoral injection.  
Drug Deliv. 2017;24(1):857-866. doi:10.1080/10717544.2017.1330373  
123. Yook S, Cai Z, Lu Y, Winnik MA, Pignol JP, Reilly RM. Intratumorally injected 
177Lulabeled gold nanoparticles: Gold nanoseed brachytherapy with application for 
neoadjuvant treatment of locally advanced breast cancer. J Nucl Med. 2016;57(6):936-942.  
doi:10.2967/jnumed.115.168906  
124. Durymanov MO, Rosenkranz AA, Sobolev AS. Current approaches for improving 
intratumoral accumulation and distribution of nanomedicines. Theranostics.  
2015;5(9):1007-1020. doi:10.7150/thno.11742  
125. Adam Moser, Kevin Range  and DMY. 基因的改变 NIH Public Access. Bone.  
2008;23(1):1-7. doi:10.1038/jid.2014.371  
126. NANOPARTICLE-BASED CHEMOTHERAPY. 2015;(August).  
127. Makadia HK, Siegel SJ. Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable  
Controlled Drug Delivery Carrier. Polymers (Basel). 2011;3(3):1377-1397.  
doi:10.3390/polym3031377  
  110  
128. Panyam J, Dali MM, Sahoo SK, et al. Polymer degradation and in vitro release of 
a model protein from poly(D,L-lactide-co-glycolide) nano- and microparticles. J Control 
Release.  
2003;92(1-2):173-187. doi:10.1016/s0168-3659(03)00328-6  
129. Khanna V, Kalscheuer S, Kirtane A, Zhang W. Perlecan-targeted nanoparticles for 
drug delivery to triple-negative breast cancer. 2019;1.  
130. 2018 NCI Budget Fact Book - Research Funding - National Cancer Institute.  
https://www.cancer.gov/about-nci/budget/fact-book/data/research-funding. Accessed 
December 9, 2019.  
131. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 
2018;68(1):7- 
30. doi:10.3322/caac.21442  
132. Cheng J, Teply BA, Sherifi I, et al. Formulation of functionalized PLGA-PEG 
nanoparticles for in vivo targeted drug delivery. Biomaterials. 2007;28(5):869-876. 
doi:10.1016/j.biomaterials.2006.09.047  
133. Chu X, Wang Y, Meng W, Chen L, Jin M, Chen L. Improving antitumor outcomes 
for palliative intratumoral injection therapy through lecithin – chitosan nanoparticles 
loading paclitaxel – cholesterol complex. 2019.  
  
  
   
